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INTRODUCTION:  
The human Polyomavirus BK virus (BKV) is an opportunistic pathogen which causes 
significant morbidity and mortality in immunocompromised population. As HIV causes 
significant immunosuppression, it is important to determine the frequency and viral load 
of BK virus which are usually increased in these individuals. 
OBJECTIVES:  
The main objective was to quantitate BK virus in urine and whole blood of treatment 
naïve HIV-1 infected individuals and to correlate the viral load with the degree of 
immunosuppression. The other objectives were to look for any NCCR rearrangements in 
BKV DNA positive urine and whole blood samples and to determine the genotype of 
these samples. The final objective was to prospectively follow up a proportion of BK 
virus positive individuals and see the effect of antiretroviral treatment on BK viral load 
by estimating the load following a minimum of 3 months on ART. 
METHODOLOGY:  
BKV DNA detection was done using In house qualitative TaqMan real time PCR on 
urine and whole blood samples collected from 187 treatment naïve HIV-1 infected 
individuals and 93 healthy HIV negative healthy individuals. Samples which were 
positive by qualitative PCR were subjected to an in house quantitative PCR to determine 
the BK viral load. All BKV PCR negative samples were subjected to an in-house ERV-3 
quantitative PCR to check the DNA integrity. Estimation of CD4 count was done on all 
blood samples. HIV RNA estimation was done on all BKV positive and a proportion of 
BKV negative plasma samples. DNA sequencing of the Non-coding Control Region 
(NCCR) was done on a proportion of BK positive samples to look for any 
rearrangements. The same samples were genotyped based on NCCR region and 5 
randomly selected samples were genotyped based on VP1 region.  
RESULTS:  
Out of the 187 paired urine and blood samples from HIV-1 infected individuals, 46 
(25.6%) urine samples and 2 (1%) blood samples were positive for BK virus. The BKV 
load range from 1-359886 copies/ml. Only 10 (10.7%) urine samples from healthy 
controls were positive for BK virus. All BKV PCR negative samples were positive for 
ERV-3. Out of the 42 urine samples subjected to NCCR sequencing, only 2 samples 
showed a rearranged NCCR with the rest of them being archetypal variant. All samples 
genotyped based on NCCR and VP1 region were genotype I. Out of the 8 follow up 
individuals on ART, 4 were negative for BK virus, 2 had decreased and 2 had increased 
BK viral load than the pre ART viral load.   
CONCLUSION:  
The frequency of BK viruria in HIV-1 infected individuals is higher than healthy 
controls. There is a strong association of BKV viruria with the extent of 
immunosuppression. The frequency and viral load of BKV among HIV infected 
individuals is very low unlike in transplant settings. NCCR rearrangements were not 
associated with high BK viral load in urine or clinically severe disease.  
Keywords: BK virus, HIV, immunosuppression, NCCR, genotype,  
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1. INTRODUCTION  
Infection caused by Human immunodeficiency virus (HIV) is one of the major health issue 
worldwide causing significant morbidity and mortality. At the end of 2014, there were 
about 36.9 million people living with HIV worldwide that has increased by 1.9 million 
from 2013. Of this 14.9 million were on ART representing 40% of the total HIV burden 
worldwide. HIV stands sixth among the top ten causes of death worldwide killing 1.2 
million people in 2014. Sub-Saharan Africa ranks first in the world accounting for about 
70% (25.8 million) of the global HIV population (1)(2). 
HIV is a Lentivirus belonging to the family Retroviridae. It is the cause of severe 
immunological deterioration which causes a wide spectrum of illness from an 
asymptomatic to advanced stage known as Acquired Immunodeficiency Syndrome 
(AIDS). This is defined by the presence of opportunistic infections, neoplasms and life 
threatening illnesses that occurs due to profound immunosuppression caused by the virus 
(3). 
There are two types of Human immunodeficiency viruses – HIV-1 and HIV-2. A majority 
of infections worldwide is caused by HIV-1 which was identified in 1983 by two separate 
scientists. In 1986, a second retrovirus which was distinct from HIV-1 was identified in 
West Africa and was named as HIV-2. About 40-60% sequence homology is seen between 
HIV-1 and HIV-2 (4). The rate of transmission and the extent of clinical disease are much 
lower with HIV-2 than HIV-1 (5). 
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HIV-1 is transmitted by various modes such as sexual, parenteral by exposure to infected 
body fluids and mother to child transmission (3). HIV-1 targets the immune cells especially 
CD4+ T helper cells which acts as the receptor for the virus. After entry, there is a rapid 
and persistent replication, depleting this subset of T cells by various direct and indirect 
mechanisms. As there is an imbalance between the T cell production and destruction, 
intense immunosuppression occurs. This paves way for the emergence of opportunistic 
pathogens to cause various diseases (6). 
Opportunistic infections usually occur in individuals with depleted immune system, 
mediated by HIV. Irrespective of the CD4 count any individual who is diagnosed to have 
an opportunistic infection falls into the advanced stage of HIV known as AIDS (7). The 
common opportunistic infections are 
 Bacterial infections mainly pulmonary and extra pulmonary tuberculosis. 
 Fungal infections such as Candidiasis, Coccidioidomycosis, Cryptococcosis, 
Histoplasmosis 
 Viral infections like retinitis, oral hairy leukoplakia, EBV associated non-
Hodgkin’s lymphoma, progressive multifocal leucoencephalopathy, HHV-8 
associated Kaposi’s sarcoma  
 Protozoal infections such as chronic Cryptosporidiosis and Cystisosporiasis 
Apart from these defined infections virtually any infectious agent can cause disease in HIV, 
attributing to the immunosuppression produced by the virus. Thus HIV infected individuals 
can acquire newer viral co-infections or they can be reactivated from a  latent site and cause 
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severe morbidity and mortality (8). BK virus is one such virus which can get reactivated in 
immunosuppressed HIV-1 infected individuals..  
BK virus is a DNA virus which belongs to the Polyomaviridae family. The other important 
member of this family is the JC (John Cunningham) virus, both of which were discovered 
in early 1970s. BK virus was isolated from urine of a renal transplant patient, after whom 
it was named (9). Polyomaviruses are non-enveloped viruses, about 45nm in size with 
circular double stranded DNA with an icosahedral symmetry containing 72 capsomeres (3) 
The viral genome has three regions namely the early gene region that codes for the 
regulatory proteins, the late gene region coding for the capsid proteins and the non-coding 
control region (NCCR) which harbors the origin of replication and transcription promoters. 
The latter is prone for rearrangements which is found to be associated with a clinically 
severe disease and elevated viral load (10). 
Four genotypes of BK virus have been described based on the VP1hypervariable region. 
The defined BKV genotypes are I, II, III, and IV with genotype I being the most common 
type worldwide and genotype IV reported commonly from East Asia and Europe (11) BKV 
genotyping can also be done based on NCCR sequences, where four genotypes have been 
described (I, II, III, and IV) (12). 
The initial infection with BK virus occurs during childhood through respiratory route. It 
may be an asymptomatic infection or can present with a mild respiratory illness. After this 
the virus remains latent in the renal epithelial cells and various other sites like peripheral 
blood mononuclear cells (13,14).  
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The cell mediated immunity plays an important role in limiting the BK viral replication. 
Thus the virus remains in a quiescent state with intermittent viruria (7%) in 
immunocompetent individuals (15). It gets reactivated in various immunocompromised 
states especially in the transplant settings leading to significant nephropathy in renal 
transplant recipients and hemorrhagic cystitis in hematopoietic stem cell transplant patients 
(16). 
As HIV causes depletion of CD4 cells producing profound immunosuppression, 
reactivation of BK virus occurs with higher rates of about 20-50% viral shedding is seen 
in urine of these individuals (14) There are case reports of hemorrhagic cystitis, renal 
failure and rare reports of meningoencephalitis, retinitis and pneumonia in HIV patients 
(17–19). Reports from our country have shown 9.3% BKV positivity in renal biopsy 
specimens with viruria and viremia being 15.7 and 25%  after renal transplantation (20,21). 
The progression of disease correlates with the degree of immunosuppression (8). The major 
modes of diagnosis for BK virus associated diseases are histopathological examination of 
renal biopsy tissue for cytopathic changes, detection and quantitation of viral nucleic acid 
in urine and plasma by molecular methods and cytological examination of urine for decoy 
cells (22). 
The key element in the treatment of BKV associated disease is the reduction of 
immunosuppression either by withdrawal of the offending drug or decreasing the dosage 
of the drug (22). With respect to HIV, the most effective treatment would be the control of 
HIV with Highly Active Antiretroviral therapy (HAART) (18,23) 
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The main aim of this study was to analyze the frequency of BKV from whole blood and 
urine of ART naïve HIV infected individuals and correlating the HIV-1 viral load with 
CD4 count. The study also aims at determining the BK virus genotype and to look for 
NCCR rearrangements in a proportion of urine samples and all blood samples positive for 
BK virus. A proportion of BK positive individuals on antiretroviral therapy for a minimum 
of 3 months were also followed up to determine the effectiveness of ART on clearing the 
BK virus in these individuals. 
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1. AIM AND OBJECTIVES 
      Aim 
      To quantitate and characterize BK virus in HIV-1 infected individuals and to correlate with    
     the degree of immunosuppression. 
      Hypothesis  
      There exists a difference in the BK viral load in urine and blood of HIV -1 infected    
      individuals and this viral load is also associated with the extent of   immunosuppression. 
       Objectives  
1. To quantitate BK virus DNA load in blood and urine of treatment naïve  
HIV-1 infected individuals 
2. To correlate BK viral load in urine and whole blood of these individuals with 
CD4 counts and clinical findings (HIV WHO disease stage I, II, III, IV) 
          3. To identify the genotype of BK virus in HIV-1 infected individuals 
          4. To look at the sequence variation in the NCCR (non-coding control region) of BK  
             virus between the strains isolated from blood and urine 
         5.  To prospectively follow up a proportion of BK virus positive individuals and see   
              any effect of antiretroviral treatment on BK viral load by estimating the load  
             following a minimum of 3 months on ART. 
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3. REVIEW OF LITERATURE 
3.1 HIV and AIDS 
3.1.1 Discovery  
Earliest cases of AIDS (Acquired Immunodeficiency Syndrome) were reported way back 
in 1970s when the causative agent of the disease was a mystery. The new syndrome was 
characterized by generalized lymphadenopathy, opportunistic infections and unusual 
cancers with marked depletion of CD4+ T cells. This was brought to the public notice by 
Centre for Disease Control (CDC) in 1981 (24) Thereafter two separate groups of scientists 
under Dr. Luc Montaigner in Pasteur Institute, Paris and Dr. Robert Gallo in National 
institute of health isolated a virus from patients with AIDS presenting with generalized 
lymphadenopathy. They named it as HTLV-III and LAV (Lymphadenopathy associated 
virus) respectively. Simultaneously, a third group under Dr. Jay Levy in the University of 
California, San Francisco described the same virus in 1984 and called it ARV (AIDS 
associated Retrovirus). The virus was initially thought to be a variant of Human T Lymph 
tropic virus (HTLV) which was just then discovered by Dr. Gallo, was later proved to be a 
different retrovirus belonging to the subfamily of lentiviruses, known as Human 
Immunodeficiency Virus (HIV) (25). 
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3.1.2 Epidemiology 
3.1.2.1 Global scenario 
According to WHO, 36.9 million people were living with HIV worldwide at the end of 
2014. This has increased by 2 million from 2013 with Sub-Saharan Africa being the most 
affected region accounting for about 70% of the global burden of HIV. Deaths due to AIDS 
related causes was 1.2 million which has decreased from 1.6 million in 2012.This is 
attributed to the outreach of effective ART and decline in the death rate due to AIDS related 
causes. In 2014, 40% (14.9 million) of PLHIV were receiving ART of which 13.5 million 
were from low and middle income countries (1). 
3.1.2.2 Indian scenario 
India ranks third in the world and largest in Asia with respect to HIV prevalence. Based on 
the prevalence of HIV in antenatal mothers, it was recorded to be as low as 0.3%, which 
was actually misleading. Based on the geographical division, 118 districts had prevalence 
>1% among antenatal mothers with the highest prevalence seen in states Madhya Pradesh, 
Uttar Pradesh, West Bengal, Orissa, Rajasthan and Bihar (26,27). The four main states 
which account for about 57% of India’s HIV burden are Andhra Pradesh. Karnataka, 
Maharashtra and Tamilnadu (28) 
As of 2013, there were 21 lakh people living with HIV in India accounting for about 37% 
of deaths due to AIDS related causes worldwide (29). Majority of these people are between 
15-40 years of age and women accounting for about 39% of all infections (26). The 
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prevalence of HIV is about 6-8 times more common in high risk behaviour groups than the 
general population (30). This group constitutes the female commercial sex workers (2.7%), 
men having sex with men (4.4%), injection drug users (7.1%), transgenders and their sex 
partners (8.8%) (28) 
Apart from the high risk group, there is another group of people who play a vital role in 
the spread of HIV called the “bridging population”. This group constitutes the truck drivers 
and migrant labourers who are usually the clients of sex workers (high risk) bridge the 
general population and the high risk groups (26).  
National AIDS control Organisation (NACO) is a part of the Ministry of Health and family 
welfare that is responsible for policy formulations and implementation for prevention and 
control of HIV. First AIDS control programme was established in 1992, which aimed at 
controlling the spread of HIV infection. The current programme is the NACP-IV (2012-
2017) which mainly aims at reducing the incidence of new HIV infections by 50% by 
effective care, support and education (28,31).  
3.1.3 Structure of HIV 
The mature HIV virion is about 100nm in size and roughly spherical in shape. The rod or 
the cone shaped inner core contains two copies of single stranded positive sense RNA along 
with the important enzymes, reverse transcriptase, integrase and protease (3). The lipid 
bilayer containing various host proteins forms the outer envelope of the virus. The major 
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envelope proteins are glycoproteins, gp 120 and gp41 which form the surface and 
transmembrane spikes respectively (32)  
Figure 1: Structure of HIV-1 
 
Adapted from Harrison’s Principles of Internal Medicine (32) 
 
3.1.4 Genome 
The genome of HIV-1 is about 9.7 kb in length. It has three main genes that encode the 
structural proteins and other accessory genes that encode various proteins that are involved 
in viral replication (3) The three main structural genes are 
 The gag gene that encodes the core proteins – p24, p17, p7, p6  
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 the pol gene that encodes various enzymes such as protease (p9), reverse 
transcriptase (p51/p66) and integrase (p31)  
 the env gene that codes for the envelope glycoproteins – gp120, gp 41 and gp 160 
The gag-pol-env genes are flanked by long terminal repeats (LTR) which contains 
regulatory proteins for gene expression (32) 
The additional genes encode for the regulatory (tat, rev) and accessory proteins (nef, vif, 
vpu, vpr) are important in making the target cell adaptive to augment the viral replication 
and also to regulate the viral gene expression (32). 
3.1.5 Modes of transmission 
The three major modes of transmission of HIV are contact with infected body fluids, sexual 
transmission and mother to child transmission. Transmission largely depends upon the viral 
load and the duration of exposure to that particular body fluid (6).   
Sexual route is the most common mode of transmission of HIV accounting for about 80% 
of transmission worldwide (33).Certain high risk behaviors such as homosexuality and 
having multiple sex partners increase the likelihood of HIV transmission. The risk of HIV 
spread is increased by 300 times when there is concomitant Sexually transmitted infections 
(STI) caused by Herpes simplex-2, Hemophilus ducreyi, Treponema pallidum (6). 
Transmission of HIV by blood and blood products has reduced to a large extent after 
intense screening in transfusion and transplant settings by HIV antibody testing and 
molecular detection. Injection drug users are the high risk people who acquire infection by 
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this route. They account for about 7.14% infections in our country as of 2011 especially in 
the northeastern states (26). Mother to child transmission of HIV can occur at various 
stages, during pregnancy, labour or through breast feeding which accounts for about 5.4% 
of HIV infections in our country as of 2011 (34) 
3.1.6 Replication  
The primary targets of the virus are the immune cells namely CD4+ T lymphocytes and 
macrophages. Once the virus enters the body, the surface glycoprotein gp 120 binds to 
various chemokine receptors on the target cells. CCR5 and CXCR4 are the two main co-
receptors found on macrophages and CD4 cells respectively. This binding exposes the 
transmembrane envelope glycoprotein gp41 leading to fusion of the virion and target cells 
(33). After penetration, the enzyme machinery of the virus becomes active. The two main 
enzymes are reverse transcriptase and integrase. The single stranded RNA of the HIV is 
converted into a double stranded DNA by the reverse transcriptase which is then integrated 
with the host DNA by the integrase enzyme. Thus the virus replicates along with the host 
cell’s DNA. Following this, transcription occurs to produce mRNA which is then translated 
into viral proteins in the cytoplasm. The final steps of HIV replication include assembly of 
the immature virion to the cell surface which leaves the host cell by a process called 
budding (3,33). The mature virion that is released affects other immune cells thus 
continuing the process of replication. 
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3.1.7 Pathogenesis 
The telltale sign of HIV infection is the immunosuppression due to progressive depletion 
of CD4 cells by various direct and indirect mechanisms (6) Once the virus enters the body, 
there is massive multiplication of the virus in the target immune cells which leads to CD4 
cell damage. Despite the host’s active immune response, the virus escapes the 
immunological clearance and leads to release of virions from the destructed cells which are 
concealed in the regional lymph nodes. This occurs usually within 2-6 weeks when a 
threshold of replication is reached (35). Thus a primary viremia sets in which is 
characterized by non-specific symptoms that resembles any viral infection such as fever, 
lymphadenopathy, rash, sore throat and muscle aches. Once the infection is established, it 
persists lifelong (36) the primary viremic phase is associated with a high plasma viral load 
and a transient fall in the CD4 count (35). In proportion to the viral replication, there is 
profound immune activation by the T cells which leads to release of various 
proinflammatory cytokines like TNF-α and interleukins. This state in conjunction with the 
direct viral effects leads to dramatic depletion, impaired production and dysfunction of the 
CD4 helper cells (37). There exists a period of clinical latency after the primary infection, 
the duration of which depends upon the individual’s immune system. Once the CD4 count 
falls below 200 cells/µl, the infected individual is prone to get more opportunistic 
infections (35) and progress to an advanced stage of HIV known as AIDS.  
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Figure 2: Characteristic course of HIV infection in an untreated individual 
 
 Adapted from Pathogenesis of HIV disease, Opportunities for new prevention 
interventions, Fauci et al, 2007 (37) 
 
3.1.8 Staging of HIV  
HIV disease staging is an important tool for making decisions in treatment and monitoring 
of HIV patients. The staging can be either clinical staging based on the various clinical 
manifestations with which the patient can present or immunological staging based on CD4 
counts. Two major systems of HIV classification are widely used. The WHO classification 
system which has separate clinical and immunological staging used widely in low resource 
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setting where CD4 counts may not be available. On the other hand, CDC staging system 
combines both CD4 counts and clinical staging together (38) 
Table 1:WHO clinical staging of HIV (39) 
Stages Defining illness 
Stage 1 Asymptomatic 
Persistent generalized lymphadenopathy 
Stage 2 Moderate unexplained weight loss (10%) 
Recurrent respiratory tract infections 
Herpes zoster 
Angular chelitis 
Recurrent oral ulcerations 
Popular pruritic eruptions 
Seborrheic dermatitis 
Fungal nail infections of fingers  
 
Stage 3 Severe weight loss (>10% of presumed or measured body weight)  
Unexplained chronic diarrhoea for longer than one month 
 Unexplained persistent fever (intermittent or constant for longer 
than one month)  
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Oral candidiasis  
Oral hairy leukoplakia  
Pulmonary tuberculosis (TB) diagnosed in last two years  
Severe presumed bacterial infections (e.g. pneumonia, empyema, 
pyomyositis, bone or joint infection, meningitis, bacteremia)  
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Stage 4 Conditions where a presumptive diagnosis can be made on the 
basis of clinical signs or simple investigations  
HIV wasting syndrome 
 Pneumocystis pneumonia  
Recurrent severe or radiological bacterial pneumonia  
Chronic herpes simplex infection (orolabial, genital or anorectal 
of more than one month’s duration)  
Oesophageal candidiasis 
Extrapulmonary TB  
Kaposi’s sarcoma  
Central nervous system (CNS) toxoplasmosis  
HIV encephalopathy  
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Conditions where confirmatory diagnostic testing is 
necessary:  
Extrapulmonary cryptococcosis including meningitis  
Disseminated non-tuberculous mycobacteria infection  
Progressive multifocal leucoencephalopathy (PML)  
Candida of trachea, bronchi or lungs  
Cryptosporidiosis 
Isosporiasis  
Herpes simplex infection 
 Cytomegalovirus (CMV) infection (retinitis or of an organ other 
than liver, spleen or lymph nodes) 
 Any disseminated mycosis (e.g. histoplasmosis, 
coccidiomycosis, penicilliosis) Recurrent non-typhoidal 
salmonella septicaemia 
 Lymphoma (cerebral or B cell non-Hodgkin) 
 Invasive cervical carcinoma  
Visceral leishmaniasis 
 
 
 
 
18 
 
Table 2: CDC staging of HIV (38)  
CD4 counts Clinical stage A Clinical stage B Clinical stage C 
1. >500 cells/µl Asymptomatic, 
acute HIV or 
Persistent 
generalized 
lymphadenopathy 
(A1, A2, A3) 
Symptomatic 
conditions except 
A and C 
(B1, B2, B3) 
AIDS defining 
illnesses 
(C1,C2,C3) 2. 200-499 cells/µl 
3. <200 cells/µl 
 
Table 3: CD4 counts and its correlation with opportunistic infections (40). 
                      CD4 count                          Opportunistic infections 
200 – 500 cells/cu.mm Candidiasis, Kaposi’s sarcoma, Mycobacterium 
tuberculosis. 
< 200 cells/cu.mm Pneumocystis jirovecii pneumonia, Histoplsmosis, 
Progressive multifocal leucoencephalopathy (JC virus) 
100 – 199 cells/cu.mm Toxoplasmosis, Cryptosporidiosis, Cryptococcal 
infection. 
50 – 100 cells/cu.mm Cytomegalovirus infection 
< 50 cells/cu.mm Mycobacterium avium complex infection. 
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Opportunistic infections are infections that occurs in individuals with compromised 
immune system. CDC provides a list of opportunistic infections, which if present,  
irrespective of the CD4 count, the individual is defined to have AIDS (7). 
Apart from the listed infections, any organism can cause significant disease in HIV 
patients, which is attributed to the profound immunosuppression found in these individuals. 
The disease can either be due to newer infection or by reactivation of a latent organism (8).  
BK virus is one such virus, which belongs to the same family as JC virus (cause of PML 
in HIV) can cause significant disease in immunocompromised individuals. Case reports of 
nephropathy, hemorrhagic cystitis, meningoencephalitis have been reported to be caused 
by BK virus in HIV infected individuals (14)                                                    
 
3.2 BK virus  
BK virus is a member of the Polyomaviridae family which comprises a group of small, 
non-enveloped DNA viruses, capable of causing significant nephropathy in 
immunosuppressed individuals, especially in kidney and bone marrow transplant patients 
(9). 
3.2.1 Discovery 
Polyomaviruses (poly – many; oma - tumours) were first reported by Ludwig gross in 1953 
who found a filterable agent capable of causing tumours in experimentally infected mice. 
They named it as murine polyomaviruses (41). Since then till 1960 only three members 
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were known in this group, the murine or K Polyomavirus, Simian Virus/simian vacuolating 
virus 40 of rhesus macaques (SV40), found as a contaminant in monkey kidney cells in 
Salk polio vaccine and the rabbit kidney vacuolating virus (42).  
In the next five years, two Polyomaviruses primarily infecting humans, namely JC (John 
Cunningham) and BK viruses, were described individually by two different groups. JC 
virus was the first to be identified in 1966 in brain tissue taken from a patient with 
progressive multifocal leucoencephalopathy (43). Icosahedral shaped virus particles were 
seen in the oligodendrocytes of this brain tissue and the virus was named after the initials 
of that patient, John Cunningham (JC) (42). Unlike JC virus, BK virus was an incidental 
finding in urine of a Sudanese renal transplant patient with ureteric stenosis, collected three 
and a half months post-transplant, where they actually looked for Cytomegalovirus (9,42). 
The original strain was known as Gardner’s strain, in honor of the Virologist, Dr. Sylvia 
Gardner, from the virus research laboratory, London, UK. He first observed the viral 
inclusions under electron microscopy which showed viral particles resembling 
Papillomavirus. But later when the urine sample was inoculated in African green monkey 
kidney cells, the cytopathic effect (CPE) seen was different from that produced by 
Papillomavirus. Thereafter the new virus was identified and named after the patient’s 
initials(BK) (44).These two viruses were the only known members of this family for nearly 
40 years while eight new viruses were discovered recently in five years (2007 -2012) (45). 
 In 2007 two viruses the Karolinska institute (KIPyV) and Washington University virus 
(WUPyV) were identified in respiratory samples followed by Merkel cell polyomavirus 
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from a patient diagnosed to have Merkel cell carcinoma affecting the skin in 2008. (15) 
Another virus called the Malawi polyomavirus (MWPyV) was identified by two separate 
groups in stool samples of healthy individuals and patients with WHIM syndrome (warts, 
hypogammaglobulinemia, infections and myelokathexis). The next two polyomaviruses 
HPyV6 and HPyV7 were isolated from skin and HPyV9 from serum and skin(7) The latest 
polyomavirus discovered was Trichodysplasia Spinulosa polyomavirus (TSPyV) in 2010 
which is associated with a disease producing spiny papules on the skin, especially in 
immunosuppressed  transplant patients.(10) Therefore till date there are 32 known 
polyomaviruses, with 10 of them capable of infecting humans, but not definitely associated 
with significant disease(17) 
3.2.2 Taxonomy 
Initially polyomaviruses were placed under Papavoviridae along with Papillomaviruses, 
based on the morphology of the virion, the nature of their genome and the site of 
replication. But later it was found to have dissimilarity in the genetic organization and 
evolutionary relationship between the two viruses, making Polyomaviridae a separate 
family (46).  
The International Committee on Taxonomy of Viruses revised the taxonomy of the family 
Polyomaviridae in October 2010 which now contains 3 genera instead of the conventional 
single genus Polyomavirus. The 3 genera are Orthopolyomavirus, Wukipolyomavirus and 
Avipolyomavirus, the first two containing mammalian species and the latter containing 
avian species. The criteria used in creating these taxonomic changes are host specificity, 
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genetic organization, nucleotide sequence homology over the whole genome (81 – 84% for 
species). The two important human Polyomaviruses,  BK and JC, which show about 60-
70% sequence homology are under the genus Orthopolyomavirus  (47).  
3.2.3 Structure and genome  
Figure 3: Structure of BK virus  
 
Adapted from viralzon.expasy.org 
 
BK virus is a small, non-enveloped, DNA virus measuring about 40 – 45nm in size. The 
viral capsid is of icosahedral symmetry which consists of 72 capsomeres enclosing 
covalently closed circular double stranded DNA (48). 
The genome of the virus is about five kilobasepairs in length encased around the host cell 
derived histones. The genome is divided into 3 functional regions namely the early gene 
region, late gene region and the non-coding control region (NCCR).  
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The early gene region codes for the large T antigen (LTag) and the small T antigen (sTag) 
whose function is to enhance the viral replication and transformation (10). The mechanism 
of the large T antigen facilitating viral replication is by its binding to the tumour suppressor 
proteins, the retinoblastoma (Rb) and p53, thus enhancing the host cell entry into the cell 
cycle (49). The other proposed functions of the large T antigen includes helicase activity 
which enables unwinding the strands of DNA thus opening up the origin of replication. It 
also facilitates the expression of host cell enzymatic system such as DNA polymerase or 
alpha primase complex thus playing an important role in the viral replication (14).  
The late gene region codes for the capsid proteins namely VP1, VP2 and VP3 responsible 
for the capsid production and assembly. The VP2 and VP3 share coding sequences in the 
same reading frame whereas VP1 gene is translated in a separate reading frame. In addition, 
the late region codes for a non-structural protein called the agnoprotein. The function of 
this small cytoplasmic agnoprotein remains unclear with controversial evidence on the 
release of infectious progeny as its main function (50)(51). 
 The NCCR region contains the origin of replication (ori) and the regulatory regions which 
contain the tandem repeats designating the enhancer elements responsible for early and late 
viral transcription (44). This region is conventionally divided into four blocks as O, P, Q, 
R, and S. The O block contains the origin of replication and transcription binding sites 
while the rest of the blocks have the promoters and the enhancers of transcription control 
of early and late gene regions.  
The division of base pairs among the various blocks of NCCR (O142bp,P63bp, Q39bp, 
R63bp, S63bp) has arbitrarily been done such that an archetypal ww-NCCR strain has been 
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put forth (52). Any variations in this archetypal NCCR region in the form of point 
mutations, deletions or duplication is considered as the rearranged rr-NCCR. These 
rearrangements in the NCCR region have shown to influence on the cell permissivity and 
rate of viral replication. This has been well documented in JC virus associated PML 
(Progressive Multifocal Leucoencephalopathy) patients where pathologic lesions in brain 
were found to be severe in cases with NCCR rearrangements (44). In case of BKV 
nephropathy, NCCR rearrangements have been associated with high BK viral load, 
increased likelihood of getting histologically evident disease and  a higher degree of 
cytopathological changes (53).  
Figure 4: Schematic diagram of BKV genome. 
 
 
Adapted from The human polyomaviruses, Virological background and its clinical 
implications, Rinaldo et al, 2013 (54) 
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3.2.4 Genetic diversity  
Based on the VP1 genetic diversity, BKV has been classified into 4 major subtypes as I, 
II, III, and IV. The BKV subtype I is found to be the most prevalent type ranging about 46-
82% worldwide. The second most common subtype is the subtype IV, being prevalent in 
Asia and Europe especially reported from the Northeast Asia. The other two subtypes are 
rarely reported with the frequency ranging from 0 to 6-9% (11,55).  
The subtypes I and IV are further divided into subgroups. Subgroups of subtype I are 
Ia,Ib1,Ib2 and Ic being commonly found in Africa, South East Asia, Europe and North East 
Asia respectively and those of subtype IV are IVa1 commonly reported in strains from 
South East Asia, IVb1 from Korea, IVb2 from Japan and IVc from China (55,56). 
Four genotypes I, II, III, and IV have also been described based on NCCR sequences. But 
the geographic distribution of these NCCR based genotypes have not been well studied 
(12). 
3.2.5 Epidemiology 
Humans are the well-known host for BK virus and serological evidence has been 
considered to be the best source to study its prevalence (44,57), which was done most 
commonly by Hemagglutination inhibition(HI) assay detecting IgM and IgG against capsid 
antigen followed by complement fixation, indirect immunofluorescence and 
immunoelectroosmophoresis which was then replaced by ELISA using recombinant 
antigens and more recently with virus like particles (58). 
Infection with BK virus occurs during childhood via respiratory route, preferably after the 
disappearance of maternal antibodies. The initial infection is usually asymptomatic or with 
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a mild flu like upper respiratory illness with fever (23,59). After the primary infection, the 
virus has the ability to be latent for years in various sites, the most common being the 
kidney, especially in the renal tubular cells and urothelial cells with the detection rate of 
about 50% in healthy kidneys. The second most frequent site of latency is the peripheral 
blood mononuclear cells which is followed by brain (13,14). Seroconversion has been 
reported up to 50-60% as early as 10 years of life reaching around 90 % in adults. There 
are reports of BKV DNA detection in tonsillar tissue in children who presented with upper 
respiratory illness (9,15). By large there is no significant gender difference in the BK 
seroprevalence even though rare reports of male predominance have been found (60).  
3.2.6 Replication  
The replication of BK virus is a complex process and is poorly understood as there are only 
few evidence based studies describing the various aspects of this replication.  
The early phase of replication starts with attachment of the virus by VP1 to various cellular 
receptors such as ganglioside GD1b and GT1b containing alpha 2-8 linked sialic acid 
residues. Other receptor which has a doubtful role in attachment is the N-linked 
glycoprotein with alpha 2-3 linked sialic acid residues (61). After the first step of VP1 
binding, the virus is internalized by caveolae mediated endocytosis. Caveolae (caveolin 
containing lipid rafts) are plasma membrane folds  which are involved in various transport 
mechanisms across the cell (62).  
Following internalization, the virus enters the endoplasmic reticulum which is facilitated 
by an intact microtubule system and actin filaments within 6 to 8 hrs of infection (63). As 
BK virus is a DNA virus the replication takes place in the nucleus. The transport of this 
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virus from the endoplasmic reticulum to the nucleus occurs by an unknown mechanism. 
But it has been hypothesized that a family of proteins situated in the membrane of the 
endoplasmic reticulum (ER), called the Derlin family is responsible for this ER to nucleus 
transport of the virus. These proteins are actually involved in the transport of misfolded 
proteins from ER to the cytosol for proteosomal degradation (61). It has also been proposed 
that VP2 has a role in this transport by producing various signals localizing the virus to the 
nucleus (64).  
 In the nucleus, replication process continues with transcription of the early gene region 
producing the large T and the small t antigens where the LTag, inhibits the early gene 
expression subsequently enhancing the late gene transcription. This along with other 
proposed functions makes the surrounding receptive for viral replication. The small t 
antigen also has a considerable but not a vital role, in enhancing the lytic replication of the 
virus (65).  
The late gene region translates to produce the capsid proteins in the cytoplasm which are 
then brought back to the nucleus for viral assembly. Here is the role of agnoprotein which 
is present in the perinuclear region which is proposed to do the process of assembly. Once 
there is massive replication and production of virions, the affected cell lyses to release the 
progeny virus in the environment which will further infect new cells thus making the 
infection productive (65) 
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Figure 5: Initial steps of BK virus replication. 
 
 
Adapted from Early events during BK virus entry and assembly, Jiang et al, 2009 (61)  
3.2.7 Immunity  
The immune response elicited by the host towards a viral infection is of primary importance 
in limiting the initial viral replication and the host carrier state. The innate immune 
response comes into play even before the specific antibody response and HLA restricted T 
cell response occurs. Innate response activated through TLR-3 has a role in controlling the 
BKV infection and  eliciting an inflammatory response against BKV(66) Humoral immune 
response in BK infection is elicited by the development of neutralizing antibodies which 
has very limited role in restricting the BKV replication and in development of significant 
nephropathy (66–68).  
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Cell mediated immune response in viral infections is exhibited in various ways like 
cytotoxic activity by CD8 T lymphocytes, release of proinflammatory cytokines which 
initiates a massive recruitment of lymphocytes and direct antiviral activity thereby playing 
a potential role in limiting the viral replication (69). 
In case of BK virus infection, the cellular immunity acts on various antigenic targets mainly 
the capsid proteins (VP1, VP2, VP3), and T antigens (large and small) eliciting an effective 
immune response especially involving CD4 T cells (91%) than CD8 T cells (33%) (68). 
The CD4 cells recruited are polyfunctional. These cells have a large multiplicative capacity 
and release a wide range of cytokines especially interferons thereby effectively limiting the 
viral replication. This multifunctionality of CD4 cells is seen better in young age especially 
between 20 to 30 years thus having an age preponderance similar to antibody response to 
BK viral infection (70). In immunosuppressed individuals, especially when the cellular 
immunity is depleted as in case of HIV infection, there is reactivation of the latent BK 
virus. This along with its unrestricted replication cause viral shedding in urine and blood 
thus producing a  significant disease (67,68).  
3.2.8 Pathogenesis  
3.2.8.1 Routes of transmission 
There are various proposed modes of transmission such as transfusion of blood and blood 
products, organ transplantation, feco oral, urino oral, contact with any other body fluids. 
As the primary infection occurs through respiratory route producing a mild respiratory 
illness, the major mode of transmission is by aerosols or fomites (9,15,16). Sexual mode 
of transmission has been evidenced by detection of BK virus in genital tissues (57%) and 
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semen (95%) (15,23). Transplacental route has been documented as a potential mode of 
transmission after detection of nucleic acid in aborted fetal material and placental tissues 
by molecular techniques and demonstration of IgM antibodies in cord blood (16,23). 
3.2.8.2 Latency  
After the primary infection, BK virus is capable of being latent in forms of low replicating 
or a non-replicating dormant state in various cells over a period of time without causing 
any significant morbidity.(23)This latent state is evidenced by asymptomatic shedding  of 
the virus in urine of healthy individuals(10). The most likely sites of latency for BK virus 
are the kidneys and ureters proving the urotheliotropic nature of the virus. BK virus has 
been reported in 30 – 50% of healthy kidneys and 40% in ureteric epithelial cells. The 
second most common site of BK virus persistence is the brain, found both in normal and 
tumour tissues but in considerably low levels than found in urothelial cells. The  next 
common site following brain is the peripheral blood cells and spleen (15,23). 
3.2.8.3 Reactivation 
Human Polyomaviruses are capable of getting reactivated from the latent non replicative 
state to a high replicative state producing lytic infection. When the host immune system is 
compromised, virus reactivation occurs and when there is a high viral load, viral shedding 
in the urine and blood occurs, subsequently leading to significant disease (15). The 
consequence of BKV reactivation depends on the degree of immunosuppression.  
It ranges from asymptomatic viruria without significant morbidity in mild 
immunosuppressive states like pregnancy, old age, diabetes mellitus to severe disease 
occurring in profound immunosuppressive conditions such as bone marrow 
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transplantation, solid organ transplantation especially kidneys, Acquired 
immunodeficiency syndrome (AIDS), lymphoproliferative states, autoimmune conditions 
like systemic lupus erythematosus (15,23).   
Different patterns of pathogenic mechanisms have been explained for BK virus induced 
diseases(16)  
Figure 6: Different pathogenic mechanisms of BK virus 
 
 
 
 
Adapted from Polyomavirus BK, Hirsch HH and Steiger J, 2003 (16) 
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3.2.8.4 In transplant settings:  
As kidneys are the main site of latency for BK virus, their reactivation cause significant 
nephropathy in transplantation settings as immunosuppression in the form of chemotherapy 
sets in here. About 60% of renal transplant patients and 10-50% of hematopoietic stem cell 
transplant patients have been reported to have BK virus associated nephropathy (BKVAN) 
and late onset hemorrhagic cystitis respectively (15,48). 
There are various other determinants that influence the BK virus reactivation in transplant 
patients, such as choice and duration of immunosuppressive therapy, degree of HLA 
matching, BK virus genotype (71,72).  
In renal transplantation, with the advent of third generation immunosuppressive agents 
such as tacrolimus and mycophenolate mofetil, the incidence of BK virus associated 
interstitial nephritis has increased by about 13 fold. This proves that the choice of 
immunosuppressive regimen plays a vital role in disease pathogenesis. This combination 
of tacrolimus and mycophenolate mofetil has been hypothesized to increase the BK virus 
replication by unknown mechanisms (71) Other factors which determine the BKV disease 
in renal transplant recipients are(73) 
 Deceased donor transplant (increased cold ischemia time) 
 BKV seropositivity of donor 
 BKV seronegative pediatric recipients 
 Use of ureteric stents 
 Acute graft rejection 
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 Retransplantation for a graft loss due to polyomavirus induced nephropathy 
Following reactivation in the proximal tubular epithelial cells (primary latent site), there is 
massive multiplication of the reactivated virus resulting in lytic destruction of the affected 
cell, with spread infection to the adjacent epithelial cells. This along with fluid 
accumulation in the interstitial compartment, results in severe interstitial nephritis finally 
leading to irreversible dysfunction of renal tubular cells due to fibrosis and atrophy  (23,71) 
Apart from interstitial nephritis, BK virus has been implicated in ureteral stenosis 
accounting for about 8% in patients with allograft dysfunction (16). 
 
In bone marrow transplantation, late onset hemorrhagic cystitis has been highly associated 
with BK virus reactivation, accounting for about 10-29% in these patients (17). 
Hemorrhagic cystitis is a condition frequently seen with allogeneic hematopoietic stem cell 
transplantation than with solid organ transplantation. This can be characterized by features 
of cystitis with varying grades of hematuria. It can be an early onset disease, which is 
usually due to non-viral factors such as the use of conditioning immunosuppressive 
regimen containing cyclophosphamide/busulfan and total body irradiation which cause 
direct toxic effects to the urinary bladder mucosa causing significant morbidity within one 
week of transplantation (16,17).  
The late onset disease, which is of viral origin, usually occurs after one week to two months 
of transplantation, (16,17)with BK virus being the most common cause even though other 
determinants play a role in the pathogenesis of the disease such as Co-viral infections like 
cytomegalovirus and adenovirus, Graft versus host reaction and advanced age (74). 
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It has been proposed that the pretransplant preparative therapy reactivates the dormant BK 
virus in the tubular cells, leading to its massive multiplication and cytopathic effects. 
Indirect cellular damage occurs due to the regenerating immune system in the post-
transplant period which targets the abundant viral antigens present due to the unrestricted 
proliferation of the virus, producing severe inflammation and damage to the bladder 
mucosa. But the hypothesis of immune reconstitution mechanism does not hold well in 
lymphopenic patients, proving the role of other unknown factors in the pathogenesis of BK 
virus induced hemorrhagic cystitis (71). 
3.2.8.5 In HIV infection 
As HIV causes profound immunosuppression by invading the CD4 helper T cells which 
are the group of cells responsible for restricting BK viral replication, this subset of patients 
are prone to get BKV associated diseases. The role of BK virus in HIV infection is not well 
known even though case reports of varied clinical spectrum have been reported. This 
includes hemorrhagic cystitis and BKV associated nephropathy followed by sporadic 
reports of meningoencephalitis, retinitis and pneumonia (14,16). 
HIV-1 is capable of transactivating many viruses thus augmenting their pathogenicity by 
enhancing their viral replication by its various gene products. The most important gene is 
the Tat gene (Transcriptional transactivator) which codes for one of the regulatory proteins 
of HIV involved in the transcription elongation from HIV-1 long terminal repeat.  
Tat gene exerts its effects on replication of other viruses in two different ways by either 
directly acting on the viral promoters to activate their transcription or indirectly by 
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affecting the transcription of various cytokines involved in the genomic transcription of 
various viruses through NF-kβ  Eg: TNF-α in JC virus transcription (75).                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 
In case of HIV and BK virus co-infection, the Tat protein secreted by the affected cells 
transactivates the BKV early promoter gene by different mechanisms as shown below, 
resulting in its efficient transcription and thus increased viral replication enhancing their 
pathogenicity(76) 
 
Figure 7: HIV BK transactivation mechanisms (76) 
 
TAR – Trans activation response elements 
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3.2.8.6 In carcinogenesis 
The role of BK virus in human carcinogenesis is still controversial even though there are 
well demonstrated evidences for its oncogenic potential in animal models. BK virus 
infected hamster models have shown a variety of tumors with ependymal tumors, 
neuroblastoma, choroid plexus papilloma, osteosarcoma being the most common tumors  
(78). As Bk virus is ubiquitous and can be found even in normal tissues, there are criteria 
for proving the causative role of this kind of controversial oncogenic viruses in 
carcinogenesis. They are (79) 
 Constant presence of viral DNA in the tumor cells 
 Neoplastic transformation of cells after its transfection with the suspected viral 
genomic fragments 
 Demonstration of malignant phenotype of the transformed cells which is due to the 
specific functions expressed by the viral genome 
 Clinical and epidemiological evidence that the suspected viral infection is a 
predominant risk factor for the tumor development. 
The oncogenic potential of BK virus is proved to be due to the expression of the early 
region proteins, the large T (TAg) and the small t (tAg) antigens alone or in combination 
with other oncogenes like ras and myc genes (80,81).  
The TAg plays a vital role by binding to various families of cellular tumour suppressor 
genes such as p53 and retinoblastoma gene. p53, is an important housekeeper gene which 
has an effective check on the G1 to S transition of cell cycle especially when there is a 
DNA damage. The retinoblastoma susceptibility proteins pRb and its family members 
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p130, p107 whose primary function is to regulate the rate of cellular growth and to induce 
growth arrest when needed (81) 
The TAg binding to these proteins, functionally inactivate them causing an unchecked 
multiplication of cells subsequently leading to tumour formation. It has also been 
postulated that the TAg interaction with the growth regulatory proteins has an effect on 
the rate of cell proliferation. However, for complete malignant transformation of cells, 
a massive expression of the early gene region is required that effectively inactivates the 
tumour suppressor genes(78,81) 
The tAg on the other hand has a supplementary role in oncogenesis of BK virus. This 
acts by binding to a protein phosphatase 2A (PP2A), which is a heterotrimeric 
serine/threonine phosphatase which modulates phosphorylation signals generated by 
protein kinases. Recently, this enzyme has been considered to be a tumour suppressor 
gene in various carcinomas.  
The tAg binds to its catalytic and regulatory site of this enzyme, leading to activation 
of Mitogen Activated Protein kinase (MAPK) pathway and down regulation of Wnt/β-
catenin pathway thus causing unchecked cell proliferation(78,80) 
3.2.9 Pathology  
3.2.9.1 BKV associated nephropthy (BKVAN) 
As renal biopsy forms the gold standard for the diagnosis of BKVAN, pathological 
examination forms one of the mainstay of diagnosis of this condition (59). 
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Macroscopically, a BKV affected kidney looks slightly shrunken with ill-defined 
corticomedullary junction showing patchy fibrosis of the medulla and thin sclerosing 
cortex with fibrotic scars of varying sizes (82,83) 
Table 4: Histologic patterns of BKV associated nephropathy 
Patterns  Histological features  
A (early) Viral cytopathic changes only with minimal or no tubular 
inflammation/atrophy  
B (intermediate) Viral cytopathic changes with varying degrees of 
focal/multifocal tubular inflammation/atrophy/interstitial 
fibrosis. 
Can be subdivided according to the extent of tubular 
involvement and fibrosis 
B1 - < 25% B2 – 26-50% B3 - >50% 
C (end stage PVN) Minimal cytopathic changes with massive tubular atrophy 
interstitial fibrosis in a background of chronic inflammation 
 
Histologically, the disease is characterized by the presence of viral cytopathic changes 
in the tubular epithelial cells, which is the site of active viral multiplication. The 
affected cells show extensive necrosis with intranuclear basophilic inclusions giving a 
ground glass appearance. These cells are typically called as “decoy cells”. This feature 
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along with interstitial fibrosis gives an overall picture of tubulointerstitial 
nephritis(83,84) 
Based on the presence of cytopathic changes and degree of tubule loss, there are three 
main histological patterns A (early), B (intermediate), C (late) predicting the outcome 
of the disease.(84,85) 
 Figure 8: Histologic patterns of BKV nephropathy 
 
Adapted from Histologic patterns of Polyomavirus nephropathy, correlation with graft outcome 
and viral load, Drachenberg et al, 2004 and Polyomavirus disease in renal transplantation: 
Review of pathological findings and diagnostic methods Drachenberg et al, 2007 
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This virus induced tubular cell damage has a clinical and diagnostic significance. The   
clinical implication is that extensive tubular damage finally disrupt the basement 
membrane leading to viremia and the degree of inflammation seen with tubular injury may 
mimic an acute rejection in transplant settings. For diagnosis, the shedding of necrosed 
cells with virions are used for the cytological and  molecular studies (85). 
Other histological findings which can be seen are glomerular crescents, ischemic 
glomerulopathy and tubular microcalcifcations (84). 
3.2.9.2 Brain and lung 
Less commonly, case reports have shown that BK virus has been implicated in causing 
sub-acute meningoencephalitis and desquamating pneumonitis as these areas are rare 
sites of viral latency. 
Microscopic examination of brain tissue showed thickened fibrotic leptomeninges with 
mild astrocytosis and predominant mononuclear infiltrate.  
Main histological feature of BK pneumonitis lung was fibrosis with aggregates of 
pneumocytes inside the alveoli (83).  
3.2.10 Clinical features 
Primary infection with BK occurs in childhood, which presents as a mild respiratory 
illness, following which a long asymptomatic latent state occurs in the renal tubular cells. 
Reactivation of the virus in healthy individuals is usually rare, but asymptomatic viruria 
occurs in about 5-7% without viremia (17).  
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In immunocompromised states, there is reactivation and rapid multiplication of the virus. 
This causes significant morbidity manifesting in three different scenarios as BKV 
associated nephropathy, hemorrhagic cystitis and ureteric stenosis.(17) 
3.2.10.1 BKV associated nephropathy 
BKV nephropathy is common in renal transplant patients, with reactivation occurring in 
30-50% of patients after 3 months of transplantation. Viruria occurs in 80% of renal 
transplant patients with 5-10% progressing to nephropathy (86). This condition is rare in 
immunocompromised states other than renal transplantation, thus emphasizing the 
importance of various factors associated with transplantation in development of 
nephropathy (54) 
Patients present around 10-13 months post-transplant, with deterioration of renal function 
evidenced by the rise in creatinine (86). Typically these individuals lack features of viral 
infection such as fever or decrease in blood cell counts in spite of the high BK viral loads 
in their urine and plasma (87). The disease starts with viruria followed by viral shedding 
in plasma. Subsequently, BK virus will be found in renal tissue, leading to allograft failure 
with rates as high as 50-80% (86). 
3.2.10.2 Hemorrhagic cystitis 
BK virus associated late onset hemorrhagic cystitis occurs in about 5-10% of the allogeneic 
bone marrow transplant patients (54). Clinically patients present between 25 to 50 days 
post-transplant, with hematuria and other symptoms of urinary tract infection such as 
dysuria, increased frequency and supra pubic pain. Renal failure occurs due to obstruction 
of the urinary tract with large blood clots (87). 
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Grading of hemorrhagic cystitis 
There are 4 grades of hemorrhagic cystitis based on the clinical manifestations of the 
disease. They are (88) 
Table 5: Grades of BKV associated hemorrhagic cystitis 
Grades  Clinical manifestations 
I Microscopic hematuria 
II Macroscopic hematuria 
III Macroscopic hematuria with blood clots 
IV Deterioration of renal function due to urinary obstruction which need 
intervention 
 
3.2.10.3 Ureteric stenosis 
There are reports of ureteric stenosis due to BK virus in both renal and allogeneic bone 
marrow transplant recipients. This occurs approximately within one year of transplantation, 
seen more with patients who shed the virus in blood than aviremic patients (23). Stenosis 
can be reversible or irreversible. Reversible obstruction occurs secondary to obstruction of 
the urinary tract due to blood clots in hemorrhagic cystitis (89). Irreversible obstruction 
happens due to fibrosis following excessive inflammation and urothelial damage in BKV 
nephropathy (54). 
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3.2.11 Diagnosis  
Since its discovery in 1970, serology and urine cytology for decoy cells were used as the 
main methods of diagnosis for BKVAN till 1985 (90). Various serological tests were 
widely to detect both IgM and IgG antibodies against BK virus (58). As the primary 
infection occurs in early childhood, neutralizing antibodies were found in about 50-60% of 
children aged <10 years. The seroconversion rates reach up to 90% in adults. These 
antibodies are not protective against the disease and just indicate the previous exposure to 
BK virus (91). Thus, other diagnostic methods were adapted for the detection of BK virus. 
The first case diagnosed by histopathological examination (now the gold standard method) 
was reported from the University of Pittsburgh in 1993. The current modes of diagnosis of 
BKV associated nephropathy are urine cytology for decoy cells, molecular methods such 
as quantitative PCR and histopathological examination of biopsied tissue (90).  
3.2.11.1 Urine cytology  
This was one of the earliest methods used for the diagnosis of BK virus in transplant 
patients. The importance of cytological examination for diagnosis of various diseases was 
first described by George Papaniculou in 1945. Later the procedure was used for diagnosis 
of Polyomavirus infection by Koss et al. They called these cells as “Decoy cells” to 
discrimnate it from malignant cells (92) 
This is now used as a screening tool to monitor BKV viruria in transplant patients (8). 
When cytospin smears of urine from BKV infected individuals are stained with 
Papaniculou stain, characteristic cells with viral inclusions are seen. These are the virus 
infected epithelial cells which have large, homogenous and basophilic intranuclear 
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inclusion giving a ground glass appearance. They have a high nuclear cytoplasmic ratio 
with peripheral rim of condensed chromatin (93) 
There are four varieties of decoy cells described. They are (92) 
Table 6: Types of decoy cells 
                 Type                           Description  
Type 1 (classic variant) Large, homogenous and basophilic intranuclear 
inclusion giving a ground glass appearance 
Type 2 
(Cytomegalovirus like 
variant) 
Granular inclusion with a halo around it 
Type 3  Cells with multiple nuclei and granular chromatin 
Type 4 Cells with vesicular nuclei and condensed chromatin 
 
Thus detection of decoy cells has a reliable sensitivity of about 84 - 100% in detecting 
apparent BKVAN, but a very low positive predictive value of 29% thus requiring further 
tests to confirm the disease (72). Even though decoy cells are predominantly found in BK 
virus infections, these are not pathognomonic for this infection. It can also be found in JC 
and adenovirus infections (8). Therefore, the cause of decoy cells must be confirmed by 
molecular techniques. 
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3.2.11.2 Molecular assays 
Quantitative polymerase chain reaction (PCR) on blood and urine is considered to be more 
sensitive than urine cytology in BK virus detection (8). Viral shedding in urine has lower 
disease specificity as increased levels of viruria (20-60%) is usually observed in HIV 
infected individuals, even without significant nephropathy (54).  Thus demonstration of the 
virus in blood/plasma is considered to be the better indicator of disease and thus viral 
replication. Quantitative BKV DNA PCR has a sensitivity of 100% and specificity of 88% 
in diagnosing BKVAN (72). Higher viral loads has been found to be associated with 
increased tendency to get BKV nephritis (72). However, the cut off values for quantitation 
of BK shedding in urine and blood has not been defined in HIV infected individuals (8). In 
case of renal transplant patients, PCR is used as an important tool for monitoring as 15-
30% of patients have detectable viral loads in their first year of transplantation (72). But 
threshold values overlap between active and resolved nephropathy thus making 
histological examination the gold standard for BKV diagnosis (84). 
3.2.11.3 Histopathology 
Histopathological examination of renal tissue forms the mainstay of diagnosis in BKV 
associated disease. As biopsy gives an indiscriminate information about the extent of renal 
damage and thus disease progression, this is considered to be the gold standard method of 
diagnosis (59). At least two core biopsies which include the medullary tissue is required 
for examination as the viral cytopathic changes can be localized (84). Typical viral 
cytopathic changes such as amorphous, basophilic intranuclear inclusions which gives a 
ground glass appearance can be observed in the urothelial and tubular epithelial cells (85). 
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Similar cytopathic changes can be seen in JCV, SV 40 and adenovirus infections which 
can be differentiated only by BKV specific immunohistochemistry (84). The damaged 
tubules show a spectrum of changes from mild inflammatory changes to necrosis and 
atrophy. Loss of renal tubules leads to massive parenchymal scarring and this along with 
fibrosis gives a picture of tubulointerstitial nephritis (85). The extent of tubular damage in 
conjunction with the cytopathic changes form the basis for the histological patterns 
described. (Patterns A, B & C) (16,59). In transplant settings, this histological grading is 
used as a prognostic marker as this represents the stage of the disease and graft outcome 
(85). 
3.2.12 Treatment  
Till date, there is no specific anti BK therapy. Various management approaches have been 
tried which all emphasize the basic keystone, reduction of immunosuppression (71). With 
the widespread use of new and effective immunosuppressive agents, the occurrence of BK 
virus associated diseases has increased in the recent years (22). The offending agents, 
tacrolimus and mycophenolate mofetil when given in combination with other 
immunosuppressive drugs make the host unable to mount an effective antiviral immune 
response. Thus the hallmark of treating BKV disease would be either reduction or 
discontinuation of the immunosuppressive therapy (22,71). This is the only approach which 
has definite role in the management of BK patients. Even this approach becomes dubious 
in the scenario of concomitant BKV disease and acute graft rejection, as reduction of 
immunosuppression causes rapid graft rejection and poor graft survival (22). But, as graft 
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rejection settles down rapidly than BKV clearance treatment of graft rejection should be 
the first priority (71) 
The other modalities of treatment which have doubtful role are the use of Leflunomide, 
Cidofovir intravenous immunoglobulins, fluoroquinolones and statins (22,71,94). 
Leflunomide is an immunomodulatory and anti-inflammatory drug which inhibits 
pyrimidine synthesis and tyrosine kinase activity. This drug has an in vitro activity on BK 
virus and has proved to reduce the incidence of graft loss when used along with 
modification of immunosuppressive therapy (71) 
The antiviral agent, Cidofovir which is primarily used against CMV retinitis has been tried 
in the management of BKV nephropathy. In vitro studies have shown that this drug acts by 
inhibiting the BK virus replication through unknown mechanisms. Because of its potent 
nephrotoxicity, its proposed use in BKV disease is controversial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
(94). Even though various studies state the use of this drug in BKV associated diseases, the 
lack of large randomized controlled trials limits its use in these settings (95,96) 
Intravenous immunoglobulin therapy is proposed to have neutralizing antibodies against 
BKV, but its role is highly controversial (94).  
Systematic reviews have shown that no added benefits have been obtained with adjunctive 
therapies such as Leflunomide or Cidofovir. Thus to conclude, with the lack of specific 
anti BK therapy and debatable role of other modalities, only reduction of 
immunosuppression is the definitive approach for the management of BKV associated 
diseases  
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4. MATERIALS AND METHODS 
This study was done at the Department of Clinical Virology, Christian Medical College 
and Hospital (CMCH), Vellore The study was approved by the Institutional Review Board 
of the  institution (Reference no IRB Min No. 8982 dated 04.08.2014) 
4.1 Study subjects 
4.1.1 HIV-1 infected individuals – treatment naive 
ART naive HIV-1 infected individuals who had come for routine CD4+ T cell estimation 
and or HIV-1 viral load were included in this study. As part of the patient management, 
these study participants were regularly visiting the clinics of our hospital departments like, 
Departments of Infectious disease, Internal medicine and Dermatology. The study was 
explained to all the participating individuals and was recruited in the study only after 
getting a written informed consent. This cross sectional study was done during a period of 
1 year (August 2014 – August 2015) 
4.1.1.1 Inclusion criteria: 
1. Adults >18yrs of age  
2. HIV-1 infected individuals (serologically confirmed by WHO/NACO strategy III))  
3. Treatment naive  
4. Individuals willing to give both blood and urine samples  
4.1.1.2 Exclusion criteria: 
1. HIV-1 infected individuals on treatment  
2. Individuals not giving consent for collection of samples  
3. Individuals < 18years of age  
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4. Pregnant women  
5. HIV-2 infected individuals 
4.1.2 HIV-1 infected individuals – post ART 
Urine and whole blood samples were collected from a proportion of HIV-1 infected 
individuals after a minimum of 3 -6 months of ART. 
4.1.3 Healthy controls  
Urine and whole blood samples were collected from healthy individuals (considered to be 
HIV negative) to look at the frequency of BK virus in this population as this is an 
opportunistic virus. 
4.2 Sample size: 
As per the frequency of BK viruria in HIV infected individuals published in Nali et al 2012 
(97), the p value (prevalence) is taken to be 18 ,q (100-p) is 82, and d the degree of precision 
taken as 6 applying in the formula, 
                          4pq/ d²  
                         4*18.7*81.3 / 36 = 169  
Even though the calculated sample size was 169, urine and blood samples were collected 
from 187 consecutive treatment naïve HIV-1 infected individuals who attend the Infectious 
Disease clinic, CMC and referred to the Department of Clinical Virology for CD4+ T cell 
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testing and or HIV-1 viral load. The samples were collected from those who gave consent 
for the study. 
Since we collected 187 patient samples, 93 (1 control for 2 patients) healthy individuals 
were recruited in the study. 
4.3 Clinical information of the study participants: 
The detailed clinical information like, patient age, sex, regional identification, HIV related 
opportunistic infections (oral candidiasis, pulmonary tuberculosis, oral hairy leukoplakia, 
Cryptococcal meningitis, Disseminated tuberculosis, lymphoma, Pneumocystis jirovecii 
(carinii) pneumonia, CMV retinitis, Oesophageal candidiasis, wasting syndrome, 
Isosporiasis, etc) were collected from the individuals’ hospital chart and they were 
classified in to different WHO clinical stages. 
4.4 Samples tested: 
1. Paired whole blood  and Urine samples from treatment naïve HIV-1 infected 
individuals (n = 187) 
2. Paired whole blood  and Urine samples from HIV-1 infected individuals after a 
minimum of 3-6 months of ART (n=8) 
3. Paired whole blood  and Urine samples from normal healthy individuals (n = 93) (1 
control for 2 patients) 
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Study algorithm 
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4.4.1 Whole blood samples: 
A total of 6-8 ml of whole blood was collected in a sterile K2 EDTA BD vacutainers (New 
Jersey, USA) for the laboratory investigation from HIV-1 infected and healthy individuals. 
Fresh whole blood was used for CD4 estimation. In parallel whole blood was stored in 
multiple aliquots of 400µl and plasma also separated as required and made into multiple 
aliquots and stored at -70˚C until testing. 
4.4.2 Urine samples: 
10 to 20ml of urine was collected in a wide mouth screw capped container from Tarsons, 
Kolkata, India. After transferring 10 ml of urine into a sterile centrifuge tube, it was 
centrifuged in a refrigerated centrifuge at 4500 rpm for 10 minutes. The supernatant was 
discarded leaving 1ml with the deposit. After mixing the left over supernatant and deposit, 
it was stored in 2 micro centrifuge tubes with 200μl each and 1ml separately in another 
microcentrifuge tube. All the 3 tubes were stored at -70°C 
4.5 Methods  
4.5.1 CD4 estimation: 
CD4 + T cell counts for the study samples were performed using the standard procedures 
by BD FACS Count system (Becton, Dickinson, San Jose, USA) with FACS Count 
CD4/CD4 SW, Version 1.0. The BD FACS Count system, using the BD FACS Count 
CD4/CD3 reagents, is a single test ready-to-use reagent tube pair containing the 
CD3monoclonal antibody with phycoerythrin (PE)-Cy5 (PE-Cy5) / CD4 with 
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phycoerythrin (PE) to determine the absolute number of helper/inducer T lymphocytes. 
The assay uses reference beads BD control kit low, medium, and high into which whole 
blood samples was added and the reading values to validate the system linearity. 
When the whole blood is added to the reagents, fluorochrome- labeled antibodies 
containing the (CD3phycoerythrin (PE)-Cy5 (PE-Cy5) / CD4 phycoerythrin (PE)) in the 
reagents bind specifically to lymphocytes surface antigens. After a fixative solution is 
added to the reagent tubes, the sample is run on the instrument here the cells come in 
contact with the laser light, which causes the fluorochrome labeled cells to fluoresce. This 
fluorescent light intensity provides the information necessary for the instrument to count 
the cells. In addition to containing the antibody reagent, the reagent tubes also contain a 
known number of fluorochrome integrated reference beads. These beads function as a 
fluorescence standard for locating the lymphocytes and also as quantitation standards for 
enumerating the cells. 
The 50µl of patient whole blood sample was added into the each reagent tubes containing 
the anti-human CD4 and anti-human CD3 monoclonal antibody reagents. Incubate the 
tubes for 60-120 minutes at room temperature (20 to 25°C) in dark condition. After the 
incubation add 50µl of fixative solution containing the 1% formaldehyde into each tube 
and again incubate for 30minutesat room temperature (20 to 25°C) in dark condition. The 
50µl of low, medium, high control was added to the reagent tube before running the tubes 
on the instrument.  If the control results are valid read the patient samples in the BD FACS 
count machine and results are generated as print outs. 
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4.5.1.1 Quality control for FACS count: 
In order to avoid any diurnal variation all the blood samples tested for CD4 estimation are 
collected only on the day of testing between 8:00 -11:00 AM. In our laboratory, two 
internal quality control (IQC) samples were run every day. The previous day’s samples 
with the lowest and the highest CD4 T cell counts were included as the controls. The 
samples were stored at room temperature (between 20° and 28°C). The IQC values of a 
given day were compared with the previous day’s values and percent variation values were 
calculated. Percent variation was calculated as follows: (count on the first day/count on the 
second day) -1 ×100. A sample showing more than 20% variation from the previous day’s 
value was considered not acceptable and the clinical samples were retested if necessary. 
Our daily quality control data from CD3 and CD4 T cell determinations show very good 
performance. In addition to 2 internal quality controls we also use commercial stabilized 
blood (BD Multi-Check control, Becton, Dickinson, San Jose, CA) as external quality 
control for routine quality control testing. The data were also analyzed for every run and 
the results were satisfactory (98). 
Our laboratory is also a participating External Quality Assessment Scheme (EQAS) 
programs under NARI/NACO.  Under this EQAS program, every year 2 batches of QC 
samples sent by National AIDS Research Institute, Pune, India (NARI)/NACO are 
estimated for their CD3, CD4 values using the Guava® Easy CD4™ System and BD 
FACSCount system the results obtained using our system was sent to NARI for evaluation. 
Since participation we always obtained values in acceptable range and passed the QC every 
time. 
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4.5.2 HIV-1 viral load estimation using Artus assay: 
4.5.2.1 RNA extraction  
The HIV-1 viral load estimation was done for the BKV positive samples using Artus 
RealArt™ HIV-1 assays (Qiagen Hamburg, Germany) using Rotor- Gene™ 6000 The 
QIAamp® Viral RNA kit was used for viral RNA extraction. The spin protocol was 
followed and before starting the assay following reagents was reconstituted with 
appropriate reagents. 
 The carrier RNA must be added to the buffer AVL before use. (Conc. of carrier 
RNA is 10μg/ml lysis buffer) Carrier RNA dissolved in buffer AVL is stable 
for 6 months at 2-8ºC and no more than 2 weeks at room temperature (To avoid 
these make multiple aliquots).  The carrier RNA added to the buffer AVL 
improves binding of viral RNA to the QIAamp membrane.  
 Buffers AW1 and AW2 are supplied as a concentrate and appropriate amount 
of ethanol (96-100%) should be added before using them.  They are stable for 
1 year when stored at room temperature.       
 The 560 μL of buffer AVL was added into a sterile 1.7 ml micro centrifuge tube 
and 140 μL of plasma was added to the buffer AVL in the microcentrifuge tube. 
Mixed by pulse-vortexing for 15 seconds and spun down at 8000rpm for 1 
minute and then incubated at room temperature (15°C-25°C) for 10 minutes.  
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 The sample was first lysed using the lysis solution (Buffer AVL) under highly 
denaturing conditions to inactivate RNases and to ensure isolation of intact viral 
RNA.  
 Then 560μL of ethanol (96-100%) was added to the sample tubes.  Mixed by 
pulse-vortexing for 15 seconds and spun down at 9000 rpm for 30 seconds. 
Buffering conditions are then adjusted to provide optimum binding of the RNA 
to the QIA amp membrane, which is a silica-gel-based membrane.  
 630μL of sample was transferred onto a QIA amp spin column without wetting 
the rim close the cap and centrifuged at 8,000 rpm for 1 minute. During this step 
the RNA binds to the silica-gel-based membrane.  
 The QIAamp spin column placed into another sterile 1.5-ml collection tube and 
discarded the tube containing the filtrate.  
 Again transferred the remaining 630μL to the QIA amp spin column and Spun 
at 8000 rpm for 1 minute then placed the QIA amp spin column into another 
sterile 1.5-ml collection tube and discarded the tube containing the filtrate.  
 Then 500 μL of AW1 (wash buffer 1) was added and spun at 8000 rpm for 1 
minute.  Placed the QIAamp spin column into another sterile collection tube and 
discarded the tube containing the filtrate. 
 Again 500 μL of AW2 (wash buffer 2) was added and spun at 14000 rpm for 3 
minutes.  Placed the QIAamp spin column into another sterile collection tube 
and discarded the tube containing the filtrate.  
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 During these steps the contaminants are washed away in two steps using two 
different wash buffers (AW1 and AW2).  Placed the QIAamp spin column into 
a clean 1.5-ml collection tube (not provided) and discarded the tube containing 
the filtrate and spin at 14000 rpm for 2 minutes.  
 The QIAamp spin column was placed into a sterile 1.5-ml micro centrifuge tube 
and added 50μL of elution buffer (RNase-free buffer (AVE)) that has been 
equilibrated to room temperature.  Incubated at room temperature for 1 minute 
and then centrifuged at 8,000rpm for 3 minutes. 
  The RNA is finally eluted out in a special RNase-free buffer (AVE). AVE has 
RNase-free water that contains 0.04% sodium azide to prevent microbial growth 
and subsequent contamination with RNases. Viral RNA is stable for up to one 
year when stored at –20°C or –70°C.   
       4.5.2.2 Master Mix reagent preparation for amplification: 
              Table 7: Reagents of Artus HI Virus-1 RG RT PCR kit 
Reagent              Use  
HIV -1 RG master A & B          Master mix 
HIV -1 RG QS 1, 2, 3 & 4         PCR standards 
HIV -1 RG IC        Internal control 
Water         PCR grade  
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The amplification of HIV-1 was done using the commercial available reagent 
Artus HI Virus-1 RG RT PCR kit which includes the following reagents as shown 
in Table 7  
 
 The cooling block must be pre-cooled to +4ºC before use.  
 The desired number of flat top PCR tubes were placed in the cooling block.  
 
 For 1 reaction add 12 μL of HIV-1 RG master A, 18 μL of HIV-1 RG master B 
and add 2 μL of HIV-1 RG IC (Internal control) were added to the sterile 1.7 ml 
micro centrifuge tubes.  
 Calculated according to the number of samples and added appropriate reagents 
into the sterile 1.7 ml micro centrifuge tubes and added 30 μL of these master 
mix reagents into desired individual number of flat top PCR tubes.  
 Then 20 μL extracted RNA was added into the appropriate labeled flat top PCR 
tubes containing the master mix reagents. 
 
  These tubes were then placed into the Rotor gene RG-3000 machine(Corbett 
Research, Mortlake, Victoria, Australia)and start the assay using the Rotor gene 
software 
The cycling conditions used for amplification are as shown Table 8 
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Table 8: Cycling conditions used for amplification in HIV load estimation by Artus 
assay 
                  Feature Temperature (ºC) Time (seconds) 
Hold 1 50 1800 
Hold 2 95 900 
 
Cycling (50 cycles) 
95 30 
50 60 
72 30 
 
 Hold 1, hold 2 and cycling was set to high speed when adjusting the profile 
(except the hold at 50°C for 60 seconds which is set at normal speed) 
 Sample numbers should then be entered and after completion of the run, the 
finding of “threshold” to determine the Ct value for the standards and each 
sample was done. 
 Any sample that was negative, checked for possible PCR inhibition. This was 
done by checking for any signals in the Cycling A ROX channel.  
 Absence of signal in both the channels indicates PCR inhibition and the sample 
must be repeated.  
Quality control: Apart from the standards provided by the kit a characterized low copy 
HIV-1 (103 copies/ml) sample was used as an in-house positive control. In all the runs the 
in-house control gave satisfactory result. Our laboratory is also a participating External 
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Quality Assessment Scheme (EQAS) programs under NARI/NACO and with UKNEQAS. 
The last years’ performance was satisfactory.  
4.6 BK specific methods: 
4.6.1 DNA Extraction: 
DNA was extracted from whole blood and urine samples using the commercially available 
QIA amp DNA blood mini kit (Qiagen, Hilden, Germany). The manufacturer’s instructions 
were strictly followed for the extraction of DNA. 
The spin protocol was followed for DNA extraction from whole blood and urine 
samples. Before starting extraction the following reagents reconstituted with 
appropriate reagents. 
 Protease reconstituted using the 5.5 ml protease solvent into the lyophilized vial 
containing the Qiagen Protease. Reconstituted Qiagen protease is stable for up to 2 
months when stored at 2–8°C. 
 Buffers AW1 and AW2 are supplied as a concentrate and appropriate amount of 
ethanol (96-100%) were added before using them.  They were stable for 1 year when 
stored at room temperature.      
Steps of DNA extraction:  
 The 20 μl of protease was added into the sterile 1.7 ml micro centrifuge tube and 
200 μl of sample was added. 
 Then 200 μl of buffer AL was added to the sample, mixed by pulse-vortexing for 
15 seconds and incubated in dry bath at 56°C for 10 minutes. 
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 The micro centrifuge tube was centrifuged to remove drops from the inside of the 
lid and added 200 μl of ethanol (96–100%) then mixed again by pulse-vortexing for 
15 seconds. 
 The sterile 1.7 ml micro centrifuge was again centrifuged to remove drops from the 
inside of the lid and carefully transferred the mixture to the QIA amp Mini spin 
column without wetting the rim. 
 The QIA amp mini spin column was centrifuged at 8000 rpm for 1 minute and 
placed the QIA amp mini spin column to a sterile 2 ml collection tube and discarded 
the tube containing the filtrate. 
 The 500 μL of AW1 (wash buffer 1) was added and spin at 8000 rpm for 1 minute.  
The QIAamp spin column was placed into another sterile 1.7-ml collection tube and 
discarded the tube containing the filtrate. 
 Again the 500 μL of AW2 (wash buffer 2) was added and spin at 14000 rpm for 3 
minutes.  The QIA amp spin column was placed into another sterile collection tube 
and discarded the tube containing the filtrate.  
 During this step the cellular debris are washed away in two steps using two different 
wash buffers (AW1 and AW2). The QIA amp spin column was placed into a clean 
collection tube and discarded the tube containing the filtrate and spin at 14000 rpm 
for 1 minute.  
 Finally the QIA amp spin column was placed into a sterile 1.7 ml micro centrifuge 
tube and added 200μL of elution buffer (AE) that has been equilibrated to room 
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temperature. The tube was incubated at room temperature for 1 minute and then 
centrifuged at 8,000 rpm for 1 minute. 
 The DNA eluted at the end of the extraction procedure was stored in aliquots at -
30˚C freezer until testing. 
4.6.2 In-house real time Real time PCR for BK virus (BKV): 
A qualitative real time PCR assay carried out for BKV in the study samples. The primer 
and probe sequences and the gene targeted used for the study is shown with references 
Table 9: Primers and probe sequences specific for VP3 gene of BK virus (99) 
Primers  Sequences   
Forward 5 ‘-TGTACGGGACTGTAACACCTGC-3’  
 
 
Reverse  5’-TTTGGMACTTGCACGGG-3’  
 
 
Probe  5’-ROX-TGAAGCATTGAAGATGGCCCCAAC-
BHQ2-3’  
 
 
 
The real time PCR was initially standardized with ROX dye as the fluorophore for BKV 
probe. The real time PCR used in this study was based on the Taq man chemistry. The Taq 
man probes are the dual labeled probes with short oligomers tagged with florescent 
reporting dye attached at 5’ end and a quencher molecule attached at the 3’ end. Since the 
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probe sequences are only 15-20 base pair length the reporter and quencher dye are in close 
proximity with each other resulting in little or no detectable florescence. During the 
amplification cycling process, the Taq DNA polymerase enzyme extends from each primer 
and due to its exonuclease activity which cleaves the downstream Taq man probe resulting 
in separation of reported dye from quencher. During every cycle the reporting dye gets 
separated with detectable fluorescence which is proportional to the amount of accumulated 
PCR product. 
BKV plasmid was used as the sources of positive controls for BKV. Sterile Milli-Q water 
control was included after every 5th place to check the PCR cross contamination. Real-time 
PCR was carried out [Rotor gene RG-3000 or RG-6000 (Corbett Research, Mortlake, 
Victoria, Australia)]. The reaction mix and cycling conditions used for the real PCR of BK 
virus is represented in Tables 10 and 11 respectively. 
Table 10: Reaction mix for in house real time PCR of BK virus 
Reaction mix  Volume  
QuantiTect Multiplex PCR NoROX master mix 12.5 µl 
BKV Forward primer (7.5 picomoles) 0.075 µl 
BKV Reverse primer (7.5 picomoles) 0.075 µl 
Taqman probe (5 picomoles) 0.05 µl 
Extracted DNA 10 µl 
Total  15 µl 
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 Table 11: Cycling conditions for in house real time PCR of BK virus 
Feature  Temperature  Time (seconds) 
Hold  95ºC 900 
 
Cycling (50 cycles) 
95ºC 45 
60ºC 75 
 
4.6.2.1 In house real time Quantitation PCR for BK virus: 
Any sample positive in the screening qualitative multiplex real-time PCR was tested by in-
house real time quantitation PCR. The PCR standards were prepared using plasmids of 
respective targets cloned using Topo TA Clone/TOP10 kit, (Invitrogen, Carisbad, USA). 
The plasmids were quantitated using the DNA spectrophotometry (BioTek Instruments, 
Vermont, USA) and then diluted serially in tenfold dilutions using milliQ water to obtain 
106 to 102 copies/ µl.  The plasmids were aliquoted in multiple tubes and stored at -30°C 
freezer. Quantification of viral DNA was carried out using the same protocol as qualitative 
PCR with respective primers and probes.  The thermal cycling conditions used were same 
as those for qualitative PCR 
The limit of detection for BK virus using In house real time PCR was ≥1 plasmid/10µl 
input.The BKV primers and probes did not show any cross reactivity with other DNA 
viruses like EBV, CMV, HSV-1, HHV-6, VZV, JC, HSV-2, HHV-8 and Adenovirus 
(100,101) 
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4.6.3 Real time PCR for Endogenous Retrovirus-3 (ERV-3): 
An in-house ERV-3 (endogenous retrovirus) qualitative real time PCR was carried out to 
check the DNA integrity for all PCR negative samples. The primers and probe was taken 
from the previously published literature (102). 
Table 12: ERV-3 specific primer and probe sequences for real time PCR 
Primers  Sequences  
Forward  PHP10-F: 5’- CATGGGAAGCAAGGGAACTAATG 
Reverse  PHP10-R: 5’- CCCAGCGAGCAATACAGAATTT 
Probe  PHP-P505: 5’- TCTTCCCTCGAACCTGCACCATCAAGTCA 
 
Table 13: Reaction mix ERV-3 real time PCR 
Ingredients  For 1 reaction 
Multiplex NOROX mix 12.5µl 
ERV-3 forward (100pm/µl) 0.075µl 
ERV-3  reverse (100pm/µl) 0.075µl 
ERV-3 probe (100pm/µl) 0.05µl 
Water  2.3µl 
Total  15µl 
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This assay was also based on the Taqman chemistry carried out using the reaction mix as 
mentioned in Table 13 with ERV-3Taqman probes containing FAM dye as its fluorophore.  
The thermal cycling conditions used were for this assay was 95°C for 15 min, 95°C for 45 
sec, and 60°C for 75 sec for 50 cycles. The assay was performed using the Rotor gene RG-
6000 (Corbett Research, Mortlake, Victoria, Australia)  
4.7 Genotyping and Analysis of BKV NCCR rearrangement methods 
The same extracted DNA utilized for real time PCR was used for genotyping and analysis 
of BKV NCCR rearrangement from a proportion of BKV positive samples to determine 
the prevalent genotypes and to look for NCCR rearrangement seen among HIV-1 infected 
individuals. 
4.7.1 Amplification of NCCR region: 
The amplification was carried out in a nested PCR format. The primer sequences were 
taken from published literature (53) 
Table 14: Outer and inner primers of BKV NCCR    
Outer primers 
1st round 
 BKTT5 5’-GAGCTCCATGGATTCTTC-3’ 
BKTT6 5’-CCAGTCCAGGTTTTACCA-3’ 
Inner primers  
2nd round 
BKTT7 5’-CCCTGTTAAGAACTTTATCCATTT-3’ 
BKTT8 5’-AACTTTCACTGAAGCTTGTCGT-3’ 
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The PCR was carried out in thermal cyclers, PTC-100 (MJ research, California, 
USA)/Veriti (Applied Biosystem, California, USA). During the first round of PCR the 
following reaction mix shown in Table 15 was used. 
Table 15: Reaction mix for the 1st round of NCCR amplification  
Ingredients  For 1 reaction (µl) 
Hot star taq master mix 25 
Outer forward 0.25 
Outer reverse 0.25 
Water  19.5 
Extracted DNA 5 
Total  50 µl 
 
Table 16: Cycling conditions used for amplification of NCCR by nested PCR 
Feature  Temperature  Time  
Enzyme activation 95° 15 minutes 
Denaturation (40 cycles) 94°C 1 minute 
Annealing (40 cycles) 55°C 1 minute 
Extension (40 cycles) 
Final extension  
72°C 
72°C 
1 minute 
10 minutes 
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The following cycling conditions were followed: 95°C for 15 min followed by 94°C for 1 
min, 55°C for 1 min, and 72°C for 1 min for 40 cycles with final extension cycle at 72°C 
for 10 min as given in Table 16. 
For the 2nd round of amplification 5 µL of 1st round PCR product was added to the sterile 
PCR tubes containing the 2.5 units of Hot star taq master mix (Qiagen, Hilden, Germany) 
and 25 picomoles of respective inner forward and inner reverse primers in a total reaction 
volume of 50 µL. The cycling conditions used are same as followed for first round of 
amplification.  
4.7.2 Agarose gel electrophoresis: 
The amplified PCR product was detected using agarose gel electrophoresis. A 2% agarose 
(Sigma Aldrich Inc, St Louis, MO, USA) gel was prepared using 100 ml of 1X TAE (Tris 
acetate EDTA buffer) containing 0.5 µg/mL of ethidium bromide.  The prepared 2% 
agarose gel was poured over the gel casting tray with appropriate gel comb.  After 30-40 
minutes the gel was placed into the electrophoresis tank equipment (Cleaver Scientific ltd, 
Warwickshire, England) containing the 1X TAE (Tris acetate EDTA) buffer and removed 
the gel comb.  The 5 µL of PCR product was mixed with 3 µL of tracking dye (bromo 
phenol blue with sucrose) and added to appropriate wells. The gel was loaded with 100-
1200 base pair range molecular weight marker (Bio basic inc, Ontario, Canada) to identify 
the PCR base pairs and run the gel placed in the electrophoresis equipment (Cleaver 
Scientific ltd, Warwickshire, England) at 120 Volts for 40-50 minutes. The PCR product 
was detected using the gel documentation system (Gel Doc, Bio Rad, California,USA) and 
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the base pairs was analyzed using the Quantity One software version 4.1.1 (BioRad, 
California, USA).  
4.7.3 Pre-cycle sequencing clean-up: 
 Pre-cycle sequencing clean-up was done using the Millipore sequencing clean up 
assay (Montage, MA, USA). 
 The Millipore plates with required number of wells were labeled for Pre-cycle 
sequencing clean up. 
 The second round PCR amplified product was made up to 100 µl final volume by 
adding sterile milli Q water. 
 The contents were mixed well and transferred onto the appropriately labeled well in 
the pre-sequencing Millipore plate. 
 The Millipore plate was connected to vacuum pump and applied negative pressure 
till the well is completely dry. 
 100 µl of sterile milli Q water was added and the previous step was repeated. 
 20 µl of the sterile milli Q water was added and the plate was placed on the shaker 
(Thermo Scientific, Barnstead/lab-line, Ashville, USA) for 2 minutes. 
 The plate was mixed and the entire contents were aspirated into a sterile 0.2ml PCR 
tube. 
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4.7.4 Sequencing PCR reaction: 
 The primers used for sequencing PCR were made up to1 picomole/µl concentration 
using sterile nuclease free water. 
  Forward and reverse primer reactions of respective viruses are set separately for 
sequencing PCR. 
 The sequencing PCR was carried out using the Big Dye Terminator Cycle 
Sequencing assay kit (Applied Biosystems, Foster City, CA). 
 The sequencing reactions were prepared with following reagents as shown below 
Table 17: Reagents used for NCCR sequencing PCR 
Reagents  For 1 reaction 
Pre-sequencing clean-up product 1.0 µl 
Primer (1picomole/µl) 3.2 µl (each primer) 
RR Master Mix    1.0 µl 
RR Buffer  2 µl 
Pyrogen free water  2.8 µl 
Total  10 µl 
 
Aliquoted 9 µl of the prepared master mix into fresh 0.2ml PCR tubes and 1 µl of the pre 
sequenced product was added to make up to a final volume of 10 µl. The sequencing PCR 
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was carried out in thermal cyclers , PTC-100 (MJ research, California, USA) or Veriti 
(Applied biosystem, California,USA),  with the  following cycling conditions: 96 ºC for 15 
seconds, 50ºC for 20 seconds, 60 ºC for 4 minutes for 25 cycles and extension cycle at  15 
ºC for 30 minutes. 
4.7.5 Post-cycle sequencing clean-up: 
 The Millipore plate was labeled with required number of wells for Post-cycle 
sequencing clean up. 
 The 30 µl of Millipore injection solution was added to sequence amplified product 
to make up to 40 µl and transferred to appropriately labeled post-sequencing 
Millipore plate.  
 The Millipore plate was connected to vacuum pump and applied negative pressure 
till the well is completely dry. 
 The 40 µl of the Millipore injection solution was added and the previous step was 
repeated. 
 The 30 µl of injection solution was added and mixed well using the titer plate shaker 
(Thermo Scientific, Barnstead/lab-line, Ashville, USA) 
 Aspirated the entire contents into a sterile 0.6ml tube and loaded the tubes into the 
ABI 310 genetic analyser (Applied Bio systems, Foster City, CA). 
The ABI 310 Genetic Analyzer (Applied Bio systems, Foster City, CA) contains a capillary 
cathode and anode.  The capillary tube was designed to touch the sample at the cathode 
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end while the anode end kept in the EDTA buffer. During the electrokinetic injection 
current is passed from the cathode to anode.  The sample passes through the detector 
window and the laser gets excited when the individual labeled fluorescent dyes passes at 
that point the fluorescence signal reading was taken. The software installed in the computer 
converts this signal in the form of electropherogram. The sequence in the form of 
electropherogram for respective viruses was bidirectionally aligned using the Finch TV 
software (version 1.4.0) and Bio Edit sequence alignment editor software version 7.0.9.0. 
These bi directionally aligned sequences are utilized for phylogenetic analyses using 
neighbour joining method with 1000 bootstrap replicates in MEGA4 software (version 
4.0). 
4.8 Control samples  
Blood and urine samples were collected from 93 (1 control for 2 patients) age and sex 
matched (as of patients) healthy individuals taken as controls, after obtaining informed 
consent for these individuals. The samples were processed in the same way as the patient 
samples and stored at -70°C. 
A separate informed consent was obtained from these individuals for HIV testing, which 
was done on their plasma samples using ErbaSure HIV gen4, a fourth generation in vitro 
enzyme immunoassay.  
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4.8.1 HIV testing on control samples 
HIV testing on all control samples was performed using ErbaSure HIV gen4 ELISA, a 
fourth generation ELISA. It was done according to the manufacturer’s instructions. 
1. The required amount of strips were taken in the frame. (microtitre plate) 
2. The negative controls (100µl) were added in wells 1A to 1D, antibody positive control 
(100µl) into well 1E and antigen positive control (100µl) into well 1F respectively. 
3. 100µl of the samples to be tested were added into the remaining wells 
4. The plate was incubated at 37°C±1°C for 60 minutes after sealing the plate with a sealer 
5. Before the last 10 minutes of incubation, a 1:51 dilution of conjugate with conjugate 
diluents is made  
6. After aspirating the contents from the wells, each well was washed 5 times with diluted 
washing solution (350 µl/well/time) 
7. The plate was tapped on the adsorbent paper to remove excess washing solution and 
100µl of prepared diluted conjugate was added into each well. 
8. The plate was incubated at 37°C±1°C for 30 minutes after sealing the plate with a sealer 
9. Before the last 5-10 minutes of second incubation, a 1:101 dilution of substrate with 
substrate buffer is made  
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10. After aspirating the contents from the wells, each well was washed 5 times with dilutrd 
washing solution (350µl/well/time) 
11. The plate was tapped on the adsorbent paper to remove excess washing solution and 
100µl of prepared substrate is added into each well and incubate at room temperature for 
30 minutes avoiding exposure to light 
12. 100 µl of stop solution was added into each well and the plate is tapped gently to 
homogenize the coloring materials. 
13. The absorbance was read at 450nm (reference wavelength at 620nm) against air within 
30 minutes after pipetting of stop solution. 
Interpretation of results: 
1. The mean of the negative control (NC) is calculated 
2. The cut off value is calculated as mean of NC + 0.2 
3. Any absorbance value above the cut off value was considered reactive to anti- HIV or 
HIV antigen. 
Only HIV negative control samples were taken for further testing. In house Qualitative BK 
PCR was done on these samples as done for patient samples. Quantitation was done on the 
positive samples and negative samples were subjected to quantitative ERV-3 PCR to check 
the DNA integrity.  
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4.9 Statistical analysis 
Chi2 test was used to see the difference in proportion of BKV positive status among 2 groups of 
HIV-1 infected individuals and HIV negative healthy controls. The two tailed t test was used to 
analyze the difference in BKV viral load among the 2 groups of HIV-1 infected individuals and 
controls. The two tailed t test probability, Welch test (for assuming unequal variance of 
independent sample) were used to analyze the viral load level and spearman’s test was used to 
determine the correlation coefficient. The data generated from the study samples using these 
statistical methods were plotted using the Box-and-whisker plot.  The percentile value, Chi2 and 
the two tailed t test analysis were done using the Medcalc software version 9.2.0.1. 
(http://www.medcalc.be). Analysis of variance for one way ANOVA was done using Epi Info 6 
version 6.04b. The univariate and multivariate analysis of all the clinical and laboratory data were 
performed using STATA 10.0 (Stata Corp, College Station, TX). A p value of < 0.05 was 
considered as significant.  
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5. Results 
Urine and whole blood samples which were collected from 187 treatment naïve HIV-1 
infected individuals and 93 HIV negative healthy individuals were tested during the study 
period. 
Findings on samples collected from HIV-1 infected and healthy individuals:  
5.1 Demographic details: 
Among the total 187 treatment naïve HIV-1 infected individuals, 86 were females and 101 
were males as represented in Figure 9. The patients’ age group ranged from 22-68 years 
with the mean age being 40 years (mean age in females = 38yrs; males = 41yrs). The age 
distribution of HIV-1 infected individuals has been shown in Table 18.  
These individuals were from different geographic regions, majority were from Tamilnadu 
(n=114, 60.9%) followed by Andhra Pradesh (n=46, 24.5%) and West Bengal (n=13, 
6.7%). The rest of the patients were from other regions as shown in the Table 19 
Out of 93 age and sex matched healthy individuals collected, (1 control for two patients) 
43 were females and 50 males as represented in Figure 10. All these individuals were from 
the state of Tamilnadu.  
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Figure 9: The pie chart showing the sex distribution of study population (HIV-1 
infected individuals) 
 
Table 18: Age distribution of study subjects (HIV-1 infected individuals) 
      Age group in years Number of subjects (%) 
20 – 30 26 (13.9%) 
31 – 40 82 (43.8%) 
41 -50 53 (28.3%) 
51 – 60 20 (10.6%) 
61 -70 6    (3.2%) 
Total 187 (100%) 
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Table 19: Geographic distribution of study population 
 
                    
 
.  
 
 
 
 
 
 
 
 
 
 
 
Region  Number Percentage 
Tamilnadu  114 60.9 
Andhra Pradesh 46 24.5 
West Bengal 13 7 
Jharkhand  4 2.1 
Bihar  3 1.6 
Kerala  2 1 
Chhattisgarh  1 0.5 
Orissa  1 0.5 
Tripura  1 0.5 
Assam  1 0.5 
Andaman and Nicobar 
islands 
1 0.5 
Total  187 100 
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Figure 10: Pie chart representing the sex distribution of healthy controls. 
 
5.2 CD4 counts 
The internal quality control values obtained in all the runs were satisfactory. The CD4 
counts of 186 HIV-1 infected individuals were only available for analysis as there was a 
technical error for one of the sample and the CD4 value could not be obtained.  The mean 
(Range 7 to 1300 cells/µl) the median CD4 count were 418 and 436 cells/ µl respectively. 
Of these 186 subjects, 74 had CD4 counts less than 350 cells/ µl and 112 above 350 cells/ 
µl. This was used as a criterion to collect follow up samples. The distribution of HIV-1 
infected individuals according to CD4 counts with 350 cells/ µl as the cut off has been 
represented in Figure 11 
 
 
n=50
54%
n=43
46%
Males Females
80 
 
5.2.1 CD4 counts of study participants based on CDC categories 
 According to CDC classification of CD4 counts, treatment naïve HIV-1 infected 
individuals were classified into 3 categories. 69 (37.1%) individuals had CD4 counts >500 
cells/ µl and were classified under category 1 with the mean and the median CD4 count 
being 676 and 641 cells/ µl respectively. The CD4 count in this group range from 501-
1300 cells/ µl. A total of 74 (39.8%) individuals were under category 2 (200-499 cells/ µl) 
who had CD4 counts ranging from 204-498 cells/ µl. The mean and the median CD4 count 
in this group is 373 and 376 cells/ µl respectively. Forty three (23.1%) out of 186 
individuals were classified under category 3 (<200 cells/ µl) with mean and median CD4 
count being 81 and 64 cells/ µl respectively.  
Figure 11: Distribution of study subjects (treatment naïve HIV-1 infected individuals) 
based on CD4 counts taken for initiation of treatment (350 cells/ µl) 
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5.2.2 Distribution of study subjects (HIV1 infected individuals) based on CDC 
classification of HIV 
Based on the CDC classification of HIV, of the total 69 under CD4 category 1, 56 (81.2%) 
individuals were under clinical category A, 12 (17.3%) under category B and one (1.4%) 
individual under category C. In CD4 category 2, among the total 74 individuals, 53 (71.6%) 
were under clinical category A, 16 (21.6%) individuals under clinical category B and five 
(6.8%) individuals under clinical category C. Of the total 43 subjects in CD4 category 3, 
six (7%) were under clinical category A, 16 (37.2%) under category B and 21 (48.8%) 
individuals under clinical category C. 
 
The mean and the median values of study subjects’CD4 counts in each CDC category has 
been given in Table 20. The distribution of HIV-1 infected individuals based on CDC 
classification of HIV is shown in Table 21 
The distribution of treatment naïve HIV-1 infected individuals based on CDC 
categorization of CD4 counts has been shown in Figure 12. 
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Figure 12: Distribution of treatment naïve HIV-1 infected individuals based on CDC 
categorization of CD4 counts in study subjects 
  
Table 20: Mean and Median of CD4 counts of HIV-1 infected individuals in each CDC 
category 
CDC category    CD4 counts of study subjects in cells / µl 
  Mean                        Median  
(1) > 500 cells/ µl    676           641 
(2) 200-499 cells/ µl   373          376 
(3) <200 cells/ µl    81           64 
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Table 21: Distribution of study subjects (HIV-1 infected individuals) based on CDC 
classification of HIV 
CD4 count 
categories 
                                    Clinical categories 
Category A, n (%) Category B, n (%) Category C, n (%) 
(1)> 500 cells/ µl A1, n=56 (30.1%) B1, n=12 (6.4%) C1, n=1 (0.53%) 
(2)200-499 cells/ µl A2, n=53 (28.5%) B2, n=16 (8.6%) C2, n=5 (2.6%) 
(3)<200 cells/ µl A3, n=6 (3.2%) B3, n=16 (8.6%) C3, n=21 (11.2%) 
 
5.3 WHO clinical staging of HIV-1 infected individuals 
Figure 13: Distribution of treatment naive HIV-1 infected individuals based on WHO 
clinical staging. 
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The clinical findings of HIV-1 infected individuals were collected from their hospital 
charts and these individuals were classified into 4 WHO clinical stages (1-4) 
Out of the 187 study participants, 115 were classified into stage 1 of which 113 were 
asymptomatic and the remaining 2 subjects had persistent generalized lymphadenopathy. 
The CD4 counts in this group ranged 92-1300 cells/µl. A total of 16 individuals were 
classified into WHO clinical stage 2. They had varied clinical manifestations such as 
Herpes zoster and oral ulcerations with CD4 counts ranging from 43-636 cells/ µl.  
Twenty nine individuals were categorized as stage 3, who had CD4 counts ranging from 
28-769 cells/ µl. Majority of them presented with Oral candidiasis followed by Pulmonary 
tuberculosis, unexplained persistent fever, severe weight loss and unexplained 
thrombocytopenia. A total of 27 individuals were grouped under clinical stage 4, who 
presented with extra pulmonary tuberculosis, oesophageal candidiasis, disseminated 
tuberculosis, invasive cervical carcinoma and CMV retinitis. 25 out of 27 individuals had 
CD4 counts < 350 cells/ µl ranging from 7- 340 cells/ µl. The remaining two individuals 
had CD4 count of 455 and 529 cells/ µl respectively. 
The distribution of study subjects (HIV-1 infected individuals) based on WHO clinical 
staging is represented in Figure 13 
WHO staging and the respective clinical manifestations observed in HIV-1 infected study 
participants are represented in Table 22 
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Table 22: WHO staging and respective clinical manifestations observed among HIV-
1 infected individuals 
WHO  
stage (n) 
Range of CD4 count 
(cells/ µl) 
Clinical manifestations observed 
1 (n=115) 92-1300 Asymptomatic (n=113) 
Persistent generalized 
lymphadenopathy (n=2) 
2 (n=16) 43-636 Herpes zoster and oral ulcerations 
3 (n=29) 28-769 Oral candidiasis, Pulmonary 
tuberculosis, unexplained persistent 
fever, severe weight loss and 
unexplained thrombocytopenia. 
 
4 (n=27) 7-340 Extra pulmonary tuberculosis 
(Lymph node tuberculosis) 
Oesophageal candidiasis, 
disseminated tuberculosis, invasive 
cervical carcinoma and CMV retinitis 
One way ANOVA analysis showed that there was a significant difference in mean CD4 
count among the four WHO clinical stages of HIV. (P value < 0.001) 
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5.4. HIV-1 RNA estimation  
The plasma HIV-1 viral load was determined for all BKV DNA positive samples (n=46) 
and a proportion of BKV negative samples (n=56). HIV-1viral load in BKV positive 
individuals ranged from 71 – 5888659 copies/ml with the mean viral load of 343405 
copies/ml. The inter assay variation of the HIV-1 real time PCR assay was estimated and 
was found to be 13%. 
The HIV RNA load and the corresponding CD4 range according to WHO clinical staging 
of HIV is represented in Table 23 
Table 23: HIV-1 viral load and corresponding CD4 range according to the WHO 
clinical stages of HIV 
WHO clinical 
stage (n) 
HIV-1 viral load 
range (copies/ml) 
Mean log10 viral 
load ± SD 
CD4 count range 
(cells/ µl) 
1 (n=66) 71-854028 3.66 ± 1.13 116-1300 
2 (n=5) 108–100816 3.66 ± 1.13 206-584 
3 (n=17) 71-489718 4.03  ± 1.32 57-769 
4 (n=14) 358–5888659 5.0   ± 1.28 24-455 
One way ANOVA analysis suggested there was a significant difference in mean of HIV-1 
viral load among four WHO clinical stages of HIV. (P value <0.001) 
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5.5 BK virus specific results and analysis 
5.5.1 Urine samples  
Real time PCR for BK virus has already been standardized and been used for routine 
diagnostic use. The runs were validated based on External and internal quality controls. 
The inter assay variation of the BKV real time PCR assay was estimated and was found to 
be 7.5%. Out of 187 samples from HIV-1 infected individuals, 48 samples were positive 
for BKV DNA with qualitative real time PCR. Further when these 48 samples were 
subjected to in house quantitative real time PCR, 46 (25.6%) samples had BK viral load 
ranging from 1- 359886 copies/ ml with the mean log10 viral load of 14322 copies/ml. 
Two samples were negative for BKV DNA on quantitation even after repeat testing. 
Out of the 93 healthy individuals who were HIV-1 negative, samples from10 (10.7%) 
individuals were positive for BKV DNA with viral load ranging from 1- 572 copies/ml. 
The mean viral load in this group was 107 copies/ml. The demographic details and BK 
viral load of healthy controls is given in Table 24 
Comparison of BK virus positivity of urine in HIV-1 infected and healthy HIV negative 
individuals showed significant difference (P value 0.003) 
5.5.2. Whole blood samples  
Out of the 187 whole blood samples from HIV-1 infected individuals, only 2 (1%) samples 
were positive for BKV DNA with viral load of 1 copy/ml each.  
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BKV DNA positivity was not seen in any of the blood samples from healthy individuals. 
The percentage of positivity and their mean viral loads detected by real time PCR from the 
urine and  whole blood samples in the HIV infected and healthy individuals is shown in 
Table 25 
Table 24: Demographic details and BK viral load of HIV negative healthy controls 
S.no Study No Age in Years / 
sex (M/F) 
BK viral load 
(copies/ml) 
1 HBKUC 26 34/M 2 
2 HBKUC 46 47/F 7 
3 HBKUC 50 39/F 2 
4 HBKUC 51 58/M 34 
5 HBKUC 56 43/M 9 
6 HBKUC 63 29/M 240 
7 HBKUC 77 35/F 1 
8 HBKUC 91 43/F 572 
9 HBKUC 92 39/F 12 
10 HBKUC 93 28/F 192 
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Table 25: The number of BKV positive urine and whole blood samples and their mean 
viral load among HIV-1 infected and HIV negative healthy individuals.   
Study 
population  
Samples  Total 
(n) 
BKV DNA 
positive,  
n (%) 
Viral load 
range 
(log10 
copies) 
Mean viral load  
Mean log10±SD 
HIV-1 infected  Urine  187 46 (25.6%) # 0 - 5.55 2.17±1.5 
 Blood  187 2   (1%) 0 0 
HIV negative 
healthy 
controls 
Urine  93 10 (10.7%) # 0 – 2.75 1.24±0.96 
 Blood  93 0 0 0 
#Comparison of BK virus positivity of urine in HIV-1 infected and HIV negative healthy 
individuals showed significant difference (P value 0.003) 
 
All 139 samples from HIV infected individuals and 83 healthy control samples which were 
negative for BK virus DNA were subjected to in house ERV-3 Quantitative real time PCR 
to check the DNA integrity of the samples. All the samples from 222 individuals were 
positive for ERV-3. 
The representative real time amplification plot for BKV DNA is shown in Figure 14  
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Figure 14: Representative real time amplification plot for quantitation of BKV DNA 
 
Legend: 
QS-1- Quantitation standard for BKV DNA (106 Copies/ml) 
QS-2- Quantitation standard for BKV DNA (105Copies/ml) 
QS-3- Quantitation standard for BKV DNA (104 Copies/ml) 
QS-4- Quantitation standard for BKV DNA (103 Copies/ml) 
QS-5- Quantitation standard for BKV DNA (102 Copies/ml) 
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The representative real time amplification plot for ERV-3 is shown in Figure 15 
Figure 15: Representative real time amplification plot for quantitation of ERV-3 
  
Legend  
QS-1- Quantitation standard for ERV-3 (106 Copies/ml) 
QS-2- Quantitation standard for ERV-3 (105Copies/ml) 
QS-3- Quantitation standard for ERV-3 (104 Copies/ml) 
QS-4- Quantitation standard for ERV-3 (103 Copies/ml) 
QS-5- Quantitation standard for ERV-3 (102 Copies/ml) 
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5.6.1 Association of BK viral load and HIV-1 viral load 
 Regression plot analysis of BKV load and HIV load in log copies in BKV DNA positive 
HIV-1 infected individuals did not show the best agreement (r=0.36, n=45) (P value 0.37) 
5.6.2 Comparison of BKV DNA load between HIV-1 infected individuals and healthy 
controls  
When BKV DNA load of HIV-1 infected individuals were compared with that of HIV 
negative healthy individuals, there was a significant difference with a P value of 0.02. The 
regression plot representing the comparison of BK viral load with HIV viral load in BKV 
DNA positive HIV1 infected individuals is shown in Figure 16. 
Figure 16: Comparison of BKV load and HIV-1 load in BKV DNA positive treatment 
naïve HIV-1 infected individuals using regression plot analysis 
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The box and whisker plot showing the BKV load comparison between HIV-1 infected 
individuals and healthy controls is shown in Figure 17. 
Figure 17: Box and whisker plot for comparison of BKV load in HIV-1 infected 
individuals and HIV-1 negative healthy controls 
 
 
5.6.3 BK positivity and WHO staging 
Among the total 115 HIV-1 infected individuals under WHO clinical stage 1, 24 (20.8%) 
individuals showed detectable BKV DNA - 22 (19%) in urine and 2 (1.7%) in whole blood. 
The BKV load in this category range from 1-87368 copies/ml. Of 16 individuals in stage 
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2, 3 (18.8%) individuals showed BKV DNA positivity with viral load range from 3-359886 
copies/ml. 7 (24%) out of 29 subjects in clinical stage 3 were positive for BKV DNA with 
viral load ranging from 8-95645 copies/ml and 14 (51.8%) out of 27 individuals in stage 4 
had BKV DNA in their urine samples with viral load 1-27837 copies/ml. 
The percentage positivity and mean BK load of HIV-1 infected individuals is represented 
in Table 26 
BKV load observed in the asymptomatic stage 1 and that of symptomatic stages (2, 3, and 
4) showed significant difference in the viral load (P value 0.005) with higher viral load in 
the symptomatic group.   
Table 26: BKV positivity and their mean viral load of HIV-1 infected individuals 
categorized based on WHO clinical stages 
BKV DNA Positivity 
and mean viral load  
                               WHO staging  
1 (n=115) 2 (n=16) 3 (n=29) 4 (n=27) 
Positive samples 
Percentage positivity 
24  
20.8% 
3  
18.8% 
7 
24% 
14 
51.8% 
Mean log 10 copies ± 
SD  
1.70±1.41* (2.82±1.56 3.03±1.68 2.32±1.23)* 
* BKV load observed in the asymptomatic stage 1 and that of symptomatic stages (2,     3, 
and 4) showed significant difference in the viral load (P value 0.005) with higher viral 
load in the symptomatic group.   
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 One way ANOVA analysis showed that there was a significant difference in mean of BK 
viral load among the four WHO clinical stages of HIV. (P value < 0.001) 
 
5.6.4 Comparison of BK viral load with different variables 
The mean BK viral load was compared with different variables such as CD4 count (350 
cells/µl as the cut off), HIV-1 viral load and WHO staging was done as shown in Table 27 
Table 27: Comparison of mean and SD between HIV-1 and BK viral load based on 
the CD4 counts and WHO staging among HIV-1 infected individuals. 
CD4 count BKV load 
range 
(copies/ml) 
Mean 
log10±SD 
HIV-1 load 
range 
(copies/ml) 
Mean 
log10±SD 
WHO stage  
<350 (25) 1-26882 2.04±1.16 71-5888659 4.69±1.23 Stage 4(n=13) 
Stage 3(n=3) 
Stage 2(n=1) 
Stage 1(n=8) 
>350 (21) 1-359886 2.82±1.32 71-489718 3.73±1.10 Stage 1(n=15) 
Stage 2(n=2) 
Stage 3(n=4) 
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The univariate analysis of BK viral load outcome showed significant negative correlation 
with CD4+ T cell counts (p value 0.026) and a positive correlation with WHO clinical 
staging (p value 0.002). The variables which were significant by univariate analysis were 
subjected for multivariate analysis. This BK viral load multivariate analysis showed 
significant correlation only with WHO clinical staging (P value 0.007) and no significance 
with CD4 counts (P value 0.64). The univariate and multivariate analysis of CD4 cell count 
and WHO staging with BK viral load as outcome is represented in Table 28  
Table 28: Univariate and multivariate analysis of CD4 cell count and WHO staging 
with BK viral load as outcome  
Variable  N  Cut off  Univariate 
analysis 
p value 
        Multivariate analysis 
 Odds ratio 95% CI P value 
Age  187 40  0.91 NI NI NI 
Sex 187 - 0.25 NI NI NI 
CD4 counts 186 350 0.02 0.81 0.3 0.64 
HIV-1 viral 
load 
102 - 0.49 NI NI NI 
WHO 
staging 
187 - 0.00 1.60 1.1 0.00 
NI – Not included 
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5.7 Findings on follow up samples from HIV-1 infected individuals after 3-6 months 
of ART  
Among the 74 HIV-1 infected individuals who had CD4 counts <350 cells/µl, Eight 
individuals who were BKV DNA positive and who came to the Department of Clinical 
Virology for CD4 counts were followed up after a minimum of 3 months of ART. These 
patients. The mean BK viral load of these individuals before starting ART was 3664 
copies/ml. Among 8 subjects, 4 were negative for BKV DNA, 2 had higher and the 
remaining 2 had lower BK viral load compared to their pre ART BK viral load levels. Thus 
6 (75%) out of 8 individuals showed an effective response of either decrease in BK viral 
load (n=2, 25%) or negativity for BK virus (n=4, 50%) with ART as represented in Figure 
18.  
The CD4 counts and BK viral load were compared before and after taking ART as shown 
in Table 29.  
Comparison of BKV viral load in log copies/ml in pre and post ART individuals using 
Paired T test showed no statistically significant difference in the viral load. (P value 0.24). 
There was no significant difference between pre ART and post ART BKV mean viral load 
(P value 0.24). This is represented as a box and whisker plot as shown in Figure 19 
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Table 29: CD4 counts and BK viral load values before and after ART in follow up 
subjects 
S.No            Pre ART values                 Post ART values 
 CD4 count 
(cells/µl) 
BK viral load 
(copies/ml) 
CD4 count 
(cells/µl) 
BK viral load 
(copies/ml) 
1. 362 1 590 0 
2. 261 1 551 0 
3, 133 9 300 34 
4. 222 88 534 0 
5. 46 582 404 20428 
6. 72 26882 297 297 
7. 312 134 807 0 
8. 45 1615 115 219 
 
Comparison of BKV viral load in log copies/ml in pre and post ART individuals using 
Paired T test showed no statistically significant difference in the viral load. (P value 0.24) 
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Figure 18: Pie chart showing the BKV outcome in follow up individuals  
 
Figure 19: Box and whisker plot for comparison of BKV mean viral load before and 
after ART in HIV-1 infected individuals 
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5.8 NCCR sequencing  
A proportion of BKV DNA positive samples were sequenced using Sanger sequencing 
method to determine any rearrangements in the BKV NCCR region. Out of 46 BKV DNA 
positive urine samples, 32 were sequenced. 2 whole blood samples which were positive for 
BKV DNA were negative for NCCR PCR even after repeated testing. To look for any 
rearrangements in blood, two whole blood archive samples positive for BKV in HIV-1 
infected individuals from our previous study were also sequenced. NCCR sequencing was also 
performed on BKV DNA positive urine samples from follow up individuals (n=4) and healthy 
subjects (n=5). All BKV nucleotide sequences showed good quality electropherogram and 
were analysed using finch TV software. The solved sequences were aligned with the 
reference archetype NCCR sequences using BioEdit software version 7.2.5. The 
representative gel picture showing BKV NCCR amplified products is given in Figure 20. 
The representative electropherogram showing NCCR sequences and VP1 sequences are 
shown in Figure 21 and Figure 22. The aminoacid alignment of BKV NCCR study 
samples using BioEdit software is shown in Figure 22. 
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Figure 20: Representative gel documentation picture showing the BKV NCCR 
amplified products 
 
Legend: 
     Lane 1-4, 6 & 8-10 – BKV NCCR amplified products – product size 233bp 
     Lane 7 - Molecular weight ladder (100-1200bp) (Bio basic Inc, Ontario, Canada) 
     Lane 12 – Positive control  
     Lane 5 & 11 – Negative control 
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Figure 21: Representative electropherogram showing NCCR and VP1 sequences of 
BK virus 
(a) NCCR sequences 
 
 
(b) VP1 sequences 
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Figure 22: The amino acid alignment of BKV NCCR study samples. The entire consensus 
sequences were aligned using Bio Edit software. All positions that agree with the consensus 
sequence are denoted by a dot (.). 
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The archetype NCCR consists of 4 sequence blocks namely P block (68bp), Q (39bp), R 
(63bp), and S block (63bp). The number in the brackets indicate the number f nucleotides 
in each block of NCCR. Two urine samples, one from a treatment naïve HIV-1 infected 
individual and the other from a follow up subject showed rearrangements in the NCCR 
region. Both the archived whole blood samples also showed NCCR rearrangements. The 
rearrangement pattern seen in our clinical strains comprised of duplication of a part of P 
(9bp) and Q (23bp) blocks of BKV NCCR. The rearrangement seen in archived blood 
sample showed duplication of almost the whole of P (60bp) and Q (35bp) blocks in one 
sample and duplication of a part of P (51bp) and Q (28bp) blocks in the other sample. 
Figure 23: Representation of archetype and rearranged BKV NCCR region observed 
in various study samples 
 
Figure 24: Representation of rearranged BKV NCCR in archived blood samples 
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The representation of the archetype and rearranged NCCR region in various study samples 
is shown in Figure 23. The rearrangements in NCCR region seen in archived blood 
samples is represented in Figure 24. The CD4 count, BKV load and HIV load of NCCR 
sequenced study samples and archived samples were compared and this is shown in Table 
30 
Table 30: Details of CD4 counts, HIV-1 and BKV load in NCCR sequenced study and 
archived samples 
 NCCR  BKV load 
range 
(copies/ml) 
CD4 counts 
(cells/µl) 
HIV load 
(copies/ml) 
 
Archetype 
Samples  (n=32) 11-359886 
(2.81±1.18) 
18-697 71-5888659 
(4.25±1.27) 
Follow up (n=3) 34-20428 
(2.66±.17) 
115-807 - 
Controls (n=5) 12-572 
(1.24±0.96) 
- - 
 
 
 
Rearranged  
Urine sample 1 29 697 87 
Urine sample 
(follow up) 
72 297 - 
Archived Blood 
sample 1 
17200 38 795041 
Archived Blood 
sample 2 
3000 6 266921 
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Though the samples showed the rearranged pattern of NCCR there was no association 
between the rearrangement and BKV viral load as the two samples showed very low BK 
copy number. 
5.9 BKV genotyping  
Out of the total 46 BKV DNA positive urine samples, 30 were genotyped based on NCCR 
gene analysis and randomly selected 5 samples were genotyped based on VP1 gene 
sequencing. Two blood samples which were positive for BKV DNA were negative for 
genotyping even after repeated testing. Genotyping was also performed on follow up samples 
(n=8) and BKV positive control samples (n=10). Two archived blood samples which were positive 
for BKV from a previous study done in our institution were also genotyped. All BKV nucleotide 
sequences showed good quality electropherogram and were analysed using finch TV 
software. The BKV genotypes were determined based on the phylogenetic analysis of BKV 
strains from the Gen bank reference sequences (BKV genotype reference numbers are as 
follows: FM995410 (I), DQ176632 (II), AB211386 (III), FM995460 (IV)). All samples 
(n=48, 100%) analysed were found to be BKV genotype I. The five samples genotyped 
based on VP1 were also identified as genotype I.  
All the samples sequenced for NCCR were submitted to Gen Bank database and obtained 
accession numbers KT728853 - KT728896.  
The phylogenetic tree showing the BKV genotypes of study samples based on NCCR gene 
analysis is shown in Figure 25 
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Figure 25: Phylogenetic tree to determine BKV NCCR genotypes in patient population. 
Reference sequences from GenBank database are identified with accession numbers. Urine 
samples sequences are shown with shaded circles (●), whole blood samples are represented 
with shaded diamond shaped icon (♦) and follow up samples with shaded squares (■). The 
phylogenetic analysis was performed in MEGA4 software using the neighbor joining 
method with a bootstrap test of 1000 replicates. The accession numbers of the reference 
sequences for BKV genotypes are as follows FM995410 (I), DQ176632 (II), AB211386 
(III), FM995460 (IV) 
The phylogenetic tree showing the BKV genotypes of study samples based on VP1 gene 
analysis is shown in Figure 26 
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Figure 26: Phylogenetic tree to determine BKV VP1 genotypes in randomly selected 
patient population. Reference sequences from GenBank database are identified with 
accession numbers. Urine samples sequences are shown with shaded circles (●). The 
phylogenetic analysis was performed in MEGA4 software using the neighbor joining 
method with a bootstrap test of 1000 replicates. The accession numbers of the reference 
sequences for BKV genotypes are as follows AB260032 (I), Z19536 (II), AB211386 (III), 
AB211387 (IV)  
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.6. Discussion  
Human Immunodeficiency Virus infection has been a formidable threat to mankind 
since its discovery. At the end of 2014, there were about 36.9 million people living with 
HIV worldwide claiming about 1.2 million lives last year (1). Among the two types of 
HIV, HIV-1 is more common globally causing severe spectrum of disease than HIV-2 
(5). HIV-1 is transmitted mainly by parenteral (contact with infected body fluids and 
unsafe injection practices), sexual and mother to child transmission (3). The virus gains 
entry into the body through specific receptors on its target cells namely, CD4+ T helper 
cells and macrophages. As it targets the immune cells, the virus causes severe 
immunosuppression leading to various infections which are collectively called as 
opportunistic infections (6). Apart from the defined opportunistic illnesses, any 
infectious agent can cause significant disease in HIV infected individuals attributing to 
the severe immunosuppression produced by HIV (59). The infection can either be a 
primary infection or reactivation of the infectious agent especially a virus from a latent 
site causing significant morbidity and mortality (8).  
 
The incidence of opportunistic infections in western countries has reduced to a large 
extent owing to the outreach of ART in those regions. Whereas in our country, these 
infections still remain an important health issue because of the resource constraints and 
lack of proper reach of ART services (103). As of 2011, there are 20.9 lakhs people 
living with HIV in India. Of them 7,68,840 people were on ART at the end of 2014 
112 
 
(104). The most common opportunistic infections among HIV infected individuals in 
India are tuberculosis and candidiasis accounting for about 64% and 58% respectively 
followed by other infections (105).Viruses are an important cause of opportunistic 
infections in HIV infected individuals. The major viral agents are Cytomegalovirus 
(CMV) causing retinitis, Epstein Barr Virus (EBV) causing lymphoma, John 
Cunningham Virus (JC virus) causing Progressive multifocal leucoencephalopathy, 
Herpes simplex and Herpes zoster infections. A study done from our institution by 
Sachithanandham et al (2009), had reported the prevalence of various opportunistic 
viruses in our part of the country. The viruses looked for in that study were CMV, HSV-
1 & 2, EBV, VZV (Varicella zoster virus), Adenovirus, JC and BK virus. The authors 
reported 68 whole blood samples from HIV infected individuals were tested using 
multiplex PCR and 72% positivity for EBV and 7% positivity for CMV was observed 
(106).  
 
Another study by the same group in 2014 where the frequency of various opportunistic 
DNA viruses in treatment naïve HIV-1 infected individuals had been studied. They 
showed a positivity for EBV in 82% and 73% in patients who had CD4 counts 
<100cells/µl and 350cells/µl respectively. CMV DNA was found in 29.6% and 2.8% 
of whole blood samples from the two groups of patients who were segregated based on 
their CD4 counts. They also found 2 BK and 2 JC virus positive whole blood samples 
in that study (101). Thus BK virus is an important opportunistic viral agent to be looked 
at in immunocompromised individuals. It is a DNA virus that belongs to the family 
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Polyomaviridae (9).The disease occurs due to reactivation of the virus from its latent 
site mainly the kidneys. The virus causes significant nephropathy in 
immunosuppressive states frequently reported in renal transplant recipients who are on 
immunosuppressive therapy (15).Following reactivation, there is rapid multiplication 
of the virus causing three major clinical scenarios namely BKV associated nephropathy 
seen commonly in renal transplant patients, late onset hemorrhagic cystitis in 
hematopoietic bone marrow transplant recipients and ureteric stenosis (17). Rarely case 
reports of meningoencephalitis, retinitis and pneumonia have been reported to be 
caused by BK virus especially in HIV infected individuals (17–19). BK viruria occurs 
in 80% of the renal transplant patients with 5-10% patients progressing to nephropathy 
after 3 months of transplantation (86).  
 
As HIV is also an immunodeficient state where there is severe depletion of CD4+ T 
cells, it is important to look for this virus in these individuals. But there are limited 
studies on the impact of BK virus in HIV. The study reported in this thesis had estimated 
the viral load burden of BK virus from urine and whole blood among HIV-1 infected 
individuals using a well characterized and evaluated in house quantitative real time 
PCR and correlating with the extent of immunosuppression. We also determined the 
effect of ART on clearance of BK virus without any BKV specific treatment. Out of 
the 187 treatment naïve HIV-1 infected individuals, urine samples from 46 (25.6%) 
individuals were found to be BKV positive which is almost the same (24%) as reported 
by Sundsfjord et al (1994) where 20 out of 82 HIV infected individuals were found to 
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be BKV DNA positive by PCR from urine samples (107). However this when compared 
to Ledesma et al (2012), study where 45 (57.7%) out of 78 urine samples collected from 
HIV infected individuals had BK viruria with viral load less than 100 copies/ml. In this 
group of patients, only 5 were treatment naïve individuals of which 3 (60%) were 
positive for BK virus detected by nested PCR (14). But we observed low frequency of 
BK viruria in treatment naïve HIV-1 infected individuals with 21 individuals showing 
BK viral load >100 copies/ml. 
 
The same group found only 1 (1.2%) plasma sample positive for  BKV DNA from an 
HIV infected individual out of the total 78 individuals (14). There are other studies that 
showed higher frequency of BKV DNA in plasma and PBMC samples from HIV 
infected individuals. A study from Iran, done by Akhgari S et al (2015), showed 16% 
(4/25) BK viremia among treatment naïve HIV infected individuals by nested PCR 
(108). Another study from Norway, has reported 4.8% (2/42) positivity in PBMC 
samples of HIV infected individuals (107).  In our study, BKV DNA was detected in 
only 2 out of 187 (1%) whole blood samples from HIV-1 infected individuals each with 
a viral load of 1 copy/ml even after testing twice. This emphasizes the reproducibility 
of our real time PCR for BK virus at low copy numbers. The frequency of viremia (1%) 
observed in the study mentioned in the thesis is almost the same as Ledesma et al (2012) 
(1.2%) but lower than the other two studies. However, when compared to these studies 
the sample matrix and treatment status were different from our study. But as mentioned 
before, Sachithanandham et al (2014), who used whole blood samples from treatment 
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naïve HIV-1 infected individuals, 2 (0.6%) individuals were positive for BK virus with 
higher BK viral load (3000 and 17200 copies/ml) (101). 
 
In renal transplant settings, the BKV associated disease starts with viruria and with 
unrestricted multiplication due to immunosuppression leads to viral shedding in plasma 
(86). The frequency of BK viremia has been reported to be about 20% after 1 year of 
transplantation (72). Viremia is considered to be a predicting factor for the development 
of nephropathy which occurs usually 1-12 weeks post-transplant finally leading to 
allograft failure (84) This increased shedding of virus in blood and associated 
nephropathy very rarely occurs in immunocompromised states other than renal 
transplantation. This emphasizes the role of various factors associated with 
transplantation in the development of nephropathy (54). In the above mentioned studies 
as well as our study, the frequency of BK viremia range from 1-5% which is much 
lower than seen in transplant settings. 
 
Akhgari S et al (2015) has observed 7 out of 8 HIV infected individuals who had BK 
viremia to have CD4 counts >200 cells/µl  (108). The BK viremia detected in one 
individual by Ledesma et al (2012), had a high CD4 count of 880cells/mm3. The CD4 
counts of two patients who showed BK viremia in our study also had CD4 counts >200 
cells/µl (327 and 667 cells/µl). The association between CD4 counts and frequency of 
viruria or BK viral load remains controversial. Akhgari S et al (2015) and Sundsfjord  
et al (1994) have reported that BK viruria is independent of CD4 counts (107,108). 
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Another study from Italy, Di Taranto et al (1997), where of the 33 HIV-1 infected 
children whose age group ranging from 3 to 7 years studied, 2 (6%) children had BK 
viruria with no correlation between CD4 counts and viruria or viral load (109). On the 
other hand, Jin et al (1995), from UK studied 101 HIV individuals, of which 45 patients 
were positive for BK virus in their urine. The highest proportion of this positive subset 
had CD4 count <200 cells/µl. So this study emphasizes that the frequency of BK viruria 
is proportional to the degree of immunosuppression (110). Sachithanandham et al 
(2014) who reported 2 BK viremic patients, found that both patients had CD4 counts < 
100cells/µl (6 and 38 cells/ µl) (101). However Ledesma et al (2012) had reported 
higher BKV positivity in patients with CD4 counts >500 cells/µl (14). In our study, 
there was a significant negative association between low CD4 counts and BKV 
positivity (P value 0.02). 
 
The association between HIV load and BKV positivity observed by Ledesma et al, 2012 
(P value 0.51) was statistically insignificant. But the author mentions about three 
treatment naïve urine BKV DNA positive HIV infected individuals, who had higher 
HIV viral load as well as BKV DNA concentration (14). According to the data retrieved 
from Sachithanandham et al (2014), the HIV load of the two ART naïve BK viremic 
individuals were higher (795041 and 266921copies/ml) emphasizing the correlation 
between the degree of immunosuppression and the presence of BK virus in blood (101).  
In the present study, when we compared the urine BKV load with HIV load (only BKV 
DNA positive individuals), there was no significant correlation (P value 0.37).  
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According to WHO, clinical staging of HIV range from asymptomatic stage to a severe 
stage, known as AIDS in which the individual has defined opportunistic infections. Behzad 
Behbahani et al (2004) has reported that 12 out of 19 (63.1%) BK positive HIV patients 
belonged to AIDS (stage 4) and the rest were asymptomatic (111). Few studies have staged 
their patients based on CDC classification of HIV where infected individuals are 
categorized into 3 groups based on CD4 count and clinical conditions at the time of 
presentation. CD4 counts > 500 cells/µl as category 1, 200-499 cells/µl as category 2 and 
<200 cells/µl as category 3 (38). According to Di Taranto et al (1997), 2 BKV positive 
children belonged to CD4 category 1 (> 500 cells/µl) (109). Similar findings were reported 
by Ledesma et al (2012) where 26 out of 45 BKV positive HIV patients had CD4 counts > 
500 cells/µl (14). Jin et al (1995) reported higher number of BKV positives in CD4 
category 3 (<200 cells/µl) (110). Akhgari S et al (2015), of the total 99 HIV infected 
individuals, 30 (30.3%) patients were under category 1, 50 (50.5%) were under category 2 
and 19(19.2%) were under CD4 category 3. Out of the 8 BKV DNA positive patients, 
viremia was found to be higher in 7 (87.5%) subjects who were either under category 1 or 
2 (≥ 200 cells/µl) (108). In our study, WHO staging when compared with the BKV 
positivity and viral load, significant difference among the four stages of HIV (P value 
<0.001) was observed with BKV percentage positivity being highest (51.8%) in stage 4. 
According to CDC classification, 101 patients were under category 1, 42 under category 2 
and 43 subjects under category 3. Among the urine BKV positive patients, majority 
(71.7%) were under category 2 or 3 with equal distribution within the two categories. Even 
though the highest percentage positivity of BK virus in HIV infected individuals was seen 
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in WHO stage 4 or CDC stage 3, none of the individuals had any clinical symptoms 
suggestive of BKV nephropathy. 
 
The effect of HAART on opportunistic infections in general is like a double edged sword. 
The frequency of these infections is much higher in treatment naïve HIV infected 
individuals than ART experienced group (105). This is because of the restoration of the 
immune system by improving the CD4 counts on ART. On the other hand, with the 
initiation of ART, the scenario of IRIS (Immune Reconstitution Inflammatory Syndrome) 
sets in which makes the patient vulnerable to various opportunistic infections within the 
first three months (105). With respect to BKV infection, reduction of immunosuppression 
plays a major role in transplant settings (22). In case of HIV, HAART has a tremendous 
effect in improving the immunosuppression even without any BK specific intervention 
(23). 
Vidal et al (2007) had reported a case of a BKV associated meningoencephalitis who had 
improved just with ART and without any BK specific treatment. Multiplex PCR was 
performed on CSF for all human herpes viruses, JC and BK viruses. PCR was done on 
brain biopsy tissue as well and BK was confirmed. Patient was started on HAART and 
there was an improvement in CD4 count from 6 to 144 cells/µl at the end of 5 months with 
regression of the brain lesions on MRI even though the patient had IRIS at that presentation. 
But IRIS improved with the continuation of ART and the patient recovered (112). Ledesma 
et al, 2012 had observed that treatment naïve individuals had higher BKV as well as HIV 
load when compared to individuals on treatment. In that study, of the total 45 urine BKV 
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DNA positive HIV infected individuals, eight patients showed BK viral load >100 
copies/ml. Of them, three treatment naïve patients were the individuals who showed 
highest BK viral load values than the other individuals. In specific, the author had also 
reported higher BKV positivity in patients receiving abacavir (P value 0.03) and efavirenz 
(P value 0.03) than other patients (14).  
 
The percentage positivity of BK viremia in HAART experienced individuals to be much 
lower than treatment naïve HIV infected individuals as observed by Akhgari S et al, 2015. 
They reported about 4 out of 74 (5.4%) BK viremia in patients on ART when compared to 
4 out of 25 (16%) in ART naïve patients (108). In our study, on follow up with individuals 
on ART, 6 out of 8 individuals had decrease or absence of BK virus following ART. When 
the BK viral load log was compared between treatment naïve and ART experienced there 
was no significant difference (P value=0.24) among the two groups. But the frequency of 
BK virus in the ART experienced group was lower emphasizing the role of ART in these 
individuals  
 
To prove the opportunistic nature of the infectious agent, it is important to determine the 
frequency of these infections in normal healthy individuals. As BK virus is an opportunistic 
virus, its positivity is found to be much lower in healthy individuals than HIV infected 
individuals. This has been reported by various studies, a study from Colorado, USA, 
Markowitz et al (1992), showed that out of the 34 HIV negative healthy individuals, 17.6% 
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were positive for BK virus and the author has given a range of 8-18% viral shedding in 
urine in healthy controls (113).  
 
Ledesma et al (2012) reported a significantly higher frequency of BK viruria in HIV 
infected individuals (51.7%) than healthy controls (21.7%) (P value 0.02) (14). Jin et al 
(1995) has not reported BK positivity in any of the healthy individuals tested. However the 
control group was smaller with only 18 individuals in this study (110). Gosert et al (2008), 
studied the frequency of BK virus in urine and plasma of 264 normal healthy blood donors. 
They found BKV positivity in 26 (9.8%) individuals only in their urine samples (53). There 
was no positivity with any of the healthy plasma samples. Behzad Behbahani et al (2004) 
reported the same finding as previously described studies as 10% of BKV positivity in 
urine of healthy controls against 25.5% in HIV infected individuals (111). Our study also 
depicts the same results as 10.7% in HIV negative healthy controls as compared to 25.6% 
in HIV infected individuals (P value 0.003) and no positivity with whole blood samples 
from HIV negative healthy controls as reported by Gosert et al (2008) (53) 
 
Non-coding Control region (NCCR) is a unique region present in Polyomaviruses. This is 
coded by the late gene region of BK virus. This region has the origin of replication, 
transcription binding sites and promoter enhancing sequences which regulate the viral 
replication (114). This region is different from the conserved protein coding regions in that 
it is prone to rearrangements due to either duplication or deletion of a part or whole of the 
sequence blocks. Since the discovery of the virus, these rearrangements have been studied 
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by repeated passaging of the virus in various cell cultures, the process which itself makes 
it vulnerable for rearrangements (115). Such rearrangements are seen mostly in patients 
who have prolonged BK viremia with high viral loads in their blood. This is explained 
commonly in renal transplant patients. The exact mechanism of such rearrangements are 
unclear and various hypotheses have been documented. One such theory is based on the 
recombination between daughter and parent strands. BKV genome replicates in a bi 
directional manner starting from the origin of replication in the NCCR. During this process, 
the newly produced daughter strands and the unreplicated parent strand are in close 
proximity leading to recombination at heterologous sites (116). According to Gosert et al 
(2008), even the presence of mutations in this region when associated with unrestricted 
replication as seen in immunocompromised hosts, the proof reading capacity of the host 
cell machinery becomes futile leading on to major rearrangements. Moreover, the 
rearranged NCCR itself increases the expression of early gene region than archetype 
variant thus leading to higher rate of replication. The author also mentions about the 
association of NCCR rearrangements with the peak plasma viral load (P value <0.001) 
(53). All the above mentioned studies were done in the renal transplant settings. In a study 
done on HIV infected individuals, Markowitz et al (1992), out of the 26 BK positive urine 
samples, 6 samples had minor NCCR rearrangements showing deletion of a small NCCR 
segment of size 10-40bp and 4 samples showed an insertion with the product being longer 
than the archetype variant. These 4 samples with major rearrangements had severe degree 
of immunosuppression as evidenced by their CD4 counts which was <200cells/µl. Out of 
the 4, three (75%) of them had higher BK viral load then the other positive samples (204, 
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1142 and 8750 copies/ml) (113). Sundsfjord et al (1994) found rearrangements in 8 out of 
22 BKV positive urine samples of which only 2 samples were confirmed by sequencing. 
Rearrangement reported in this study had a duplication of P block (50bp) which was the 
first type to be reported in clinical specimens during that period. The author also found no 
correlation between NCCR rearrangements and the degree of immunosuppression or viral 
load (107). Gosert et al (2008), a study done on renal transplant patients, revealed that 
113(15%) out of 733 plasma samples from these patients showed rearranged NCCR with 
11% showing insertions and 35% showing deletions. When they compared the frequency 
of rearrangements with the median BKV load, rearranged samples showed a significantly 
higher load (4.59×105 geq/ml) than samples showing archetype variant (1.94×104 geq/ml). 
Also when the authors examined BKV positive urine samples without concurrent viremia, 
they observed only archetype variants in these samples. They also found that the BKV 
NCCR sequences from urine of healthy blood donors also showed only an archetype 
variant (53) which matched with our study findings where the healthy control samples in 
our study did not show any rearrangements.  
 
We had two urine samples from HIV infected individuals one from treatment naïve and 
other from an ART experienced individual showing NCCR rearrangements with 
duplication of a part of P (9bp) and Q blocks (23bp). There was no correlation either with 
degree of immunosuppression (CD4 counts) or with their BK viral load (29 and 72 
copies/ml) These findings were in par with the findings of Sundsfjord et al (1994) (107). 
Two archived blood samples from HIV infected individuals retrieved from the study done 
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by Sachithanandham et al (2014) showed NCCR rearrangements. Both the individuals had 
higher HIV load (795041 and 266921copies/ml) as well as low CD4 counts (6 and 38 
cells/µl) demonstrating the positive correlation between the presence of rearrangements 
and the degree of immunosuppression. Also both the individuals had a very high BK viral 
load (3000 and 17200 copies/ml). Thus NCCR rearrangements in blood correlates better 
with BK viral load than rearrangements seen in urine samples as mentioned by Gosert et 
al (2008) (53). 
 
BKV Genotyping was done initially based on short sequence of VP1 using restriction 
fragment length polymorphism and DNA sequencing by Jin et al (1993) (117). Four 
genotypes were assigned by the authors which were not including all strains found in 
various samples subsequently. This led to the emergence of subgroups within these 
subtypes, as Ia and Ib first described by Stoner et al (2002) (118). The importance of 
genotyping still remains controversial as the exact pathogenic role of different genotypes 
are not well elucidated even though they have a role in epidemiological investigations and 
to know the origin of the virus and the evolving newer strains as described by Luo et al 
(2009) (49). However according to Nukuzuma et al (2006), BKV subtype I was found to 
replicate more efficiently in vitro in human kidney epithelial cells (119) 
 BKV genotype I is the most common genotype seen worldwide. Jin et al (1995) reported 
subtype I based on VP1 heterogeneity to be common in HIV infected individuals as they 
identified 22 out of 45 BKV DNA positive urine samples as genotype I (110). Genotyping 
based on NCCR has been done by Perets et al (2009). This was a study done on renal 
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transplant recipients where Ia, Ib1, Ib2, Ic, II, III and IV genotypes were described. The 
author has reported that genotyping based on NCCR sequences almost matches with the 
phylogenetic analysis done with VP1 region (12). Gosert et al (2008), genotyped a subset 
of rearranged NCCR samples to see the association between the NCCR rearrangements 
and the subtype determination. They found that irrespective of the rearrangements all the 
samples were identified as the same genotype as the archetype NCCR samples (53). In our 
study, we did genotyping based on NCCR sequences which revealed that all 44 samples 
genotyped were identified as genotype I. We also did genotyping based on VP1 region on 
5 samples selected randomly and identified all samples as genotype I. This was to 
demonstrate the fact explained by Perets et al (2009) as there was almost no phylogenetic 
difference between genotyping based on NCCR sequences and VP1 region. The urine and 
blood samples irrespective of the NCCR rearrangements were also identified as genotype 
I in our study. This finding was the same as found in the literature published by Gosert et 
al (2008).  
 
In conclusion, being this a first study on the prevalence of BK virus in HIV infected 
individuals in India, we found a higher frequency of BK viruria in HIV-1 infected 
individuals than HIV uninfected healthy controls. The BK viral load had a significant 
positive correlation with WHO clinical staging and a negative correlation with CD4 counts 
demonstrating the association of BKV viruria with the extent of immunosuppression as 
evidenced by other studies. The frequency and viral load of BKV observed among HIV 
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infected individuals is very low compared to what is reported in transplant patients 
following immunosuppression. We did not find any NCCR rearrangements to be associated 
with high BK viral load in urine or clinically severe disease as described in literature. 
However, individuals with NCCR rearrangements in blood sample had low CD4 counts 
and higher BK viral load. All samples which were genotyped based on NCCR and VP1 
gene analysis were identified as genotype 1 which is the most common genotype 
worldwide as described. With the small subset of individuals on ART being followed up, 
it is clear that ART has a definite role in reducing the BKV load in these individuals. 
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7. Summary and conclusions  
1. This study was done to quantitate BK virus in treatment naïve HIV-1 infected 
individuals and to correlate the viral load with degree of immunosuppression and 
WHO clinical staging.  
2. The other objectives were to look for BKV NCCR rearrangements in these 
individuals and to determine the effectiveness of ART on BKV positivity by 
prospectively following a proportion of patients after a minimum of 3-6 months 
3. Urine and whole blood samples from 187 treatment naïve HIV-1 infected individuals 
were tested for BK virus by a screening qualitative followed by quantitative real time 
PCR.  
4. Forty six urine samples (25.6%) and 2 whole blood samples (1%) were positive for 
BKV DNA among the 187 HIV infected individuals. 
5. The mean BK viral load in these 46 urine samples was 2.17±1.5 log10 copies/ml. 
6. The BK viral load of these samples showed significant negative correlation when 
compared with CD4 count (P value=0.02) by univariate analysis.  
7. On the other hand, there was a positive correlation when BK viral load was compared 
with WHO clinical staging (P value < 0.001)  
8. There was no significant correlation when BK viral load was compared with HIV 
load (P value 0.37) 
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9. Six out of eight individuals (75%) who were followed up after a minimum of 3 
months of ART showed either a decrease in BK viral load (n=2) or negativity for 
BKV DNA (n=4)   
10. The BK positivity in blood was very low (1%) that also with a very low viral load 
unlike reported in immunosuppression among transplant patients 
11. We also studied the frequency of BKV in HIV negative healthy individuals, where 
10 out of 93 (10.7%) individuals showed BKV DNA positivity in their urine with 
the mean viral load of 1.24±0.96 log10 copies/ml. 
12. The percentage positivity of BKV among the healthy controls (10.7%) and that of 
HIV-1 infected individuals (25.6%) were significant (P value < 0.001). 
13. There was a significant difference (P value=0.02) between the BKV load of HIV-1 
infected individuals and healthy controls.  
14. Out of the 42 urine samples sequenced for BKV NCCR, 2 urine samples, both from 
HIV-1 infected individuals, one from treatment naïve and other from a follow up 
individual after ART showed rearrangements. A part of P (9bp) and Q (23bp) blocks 
of NCCR were duplicated in these samples. All the other 40 samples showed 
archetype NCCR sequence. 
15. Two archived blood samples positive for BKV DNA in HIV-1 infected individuals 
from our previous study also showed two different patterns of NCCR 
rearrangements. Almost the whole of P (60bp) and Q blocks (35bp) was duplicated 
in one sample and the other sample showed duplication of a part of P (51bp) and Q 
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(28bp) blocks. This was done to look for rearrangements in blood, as the present 
study’s whole blood samples could not be amplified in terms of low viral load. 
16. NCCR rearrangements were not found to be associated with high BK viral load in 
urine or clinically severe disease as described in literature.  
17. However, individuals with NCCR rearrangements in blood sample had low CD4 
counts and higher BK viral load. 
18. All samples (n=44) which were genotyped based on NCCR sequences were 
identified as genotype I and this was confirmed by genotyping 5 randomly selected 
samples with VP1 based genotyping. 
 
Limitation of the study: More number of HIV-1 infected individuals after ART need 
to be followed up to determine the true impact of HAART on declining the BK viral 
load or on complete clearance of the virus. 
Conclusion: 
In conclusion, being this a first study on the prevalence of BK virus in HIV infected 
individuals in India, we found that the frequency of BK viruria as well as the mean viral 
load are higher in HIV-1 infected individuals than HIV negative healthy individuals. 
Unlike in transplant patients with immunosuppression as reported, the viremia is 
negligible among HIV infected individuals. The BKV DNA load has a significant 
negative correlation with their CD4 counts and significant positive correlation with 
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WHO clinical staging. This proves that there is a significant correlation between the 
extent of immunosuppression and BKV viruria as evidenced by other studies. We did 
not see any NCCR rearrangements to be associated with high BK viral load in urine or 
clinically BK virus specific severe disease as described in literature. However, 
individuals with NCCR rearrangements in blood sample had low CD4 counts and higher 
BK viral load. All samples which were genotyped based on NCCR and VP1 gene 
analysis were identified as genotype 1 which is the most common genotype worldwide 
as described. With the small subset of individuals on ART being followed up, it is clear 
that ART has a definite role in reducing the BKV load in these individuals.  
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                                       PATIENT INFORMATION SHEET 
Study title: Virological characterization of BK virus among HIV-1 infected individuals 
and its association with immunosuppression.  
Please read this carefully. It tells you important information about the study. A member 
of the research team will explain you about your participation in this study.  If you have 
any questions about the research or about this form, please ask us. If you decide to take 
part in this study, you must sign or provide your thumb impression in this form to show 
your willingness to take part in this study.  
Why is this study being done? 
BK virus is an important cause of various diseases in persons infected with HIV/AIDS. 
This virus infects individuals when they are very young through respiratory tract and at 
that time the virus will not cause any disease. However, this virus will remain in the 
kidneys without multiplication. When the immunity of a person goes down, this virus 
gets reactivated and cause disease mainly affecting the kidneys.  HIV is a viral infection 
which causes severe immunosuppression (lowers immunity). So this condition 
predisposes the individual to various infections and one among that is BK virus 
associated kidney disease. So in this study we are going to look at the amount 
(quantitation) of BK virus in blood and urine of HIV infected individuals and its 
association with the clinical manifestations. We will also look at the presence of this 
virus in healthy adults (controls). 
What will happen in this study? 
Individuals above 18 years, either sex, who are serologically positive for HIV but not on 
treatment and 85 healthy individuals who are HIV negative, will be recruited in this 
study. 
If you agree to participate and you meet all the criteria required for the study either as 
patient/control, blood and urine samples will be collected from you to test for the 
presence of BK virus. 
Basic information, medical history and details of treatment will be collected from you. 
Will I be paid to take part in this study? 
You will not be paid for providing your sample for this research.     
What are the risks and possible discomforts from being in this study? 
Blood collection is done routinely for CD4+ T cell count estimation and at that time an 
additional 6ml of blood will be collected. No additional risk is associated with this 
procedure. Urine samples will be collected from you in the Department of Clinical 
Virology, with your consent to participate in the study. 
What are the possible benefits from being in this study? 
By being a part of this study, you will not benefit directly with regard to the immediate 
management of the disease, but as a result of your participation, we will be able to confirm the 
presence or absence of the virus under study and the response of this viral infection to HIV 
treatment.  If you are found positive for BK virus in blood you can be referred to the 
Department of Nephrology for standard care.  
If I take part in this research study, how will you protect my privacy? 
Information collected from you for this research study will be stored in the 
investigator’s research files. Your name and other information that might identify you 
will be recorded with a unique code number, protecting your identity and information 
from others. The research consent form that you sign may be inspected by the 
regulatory agencies or the Institutional Review Board in the course of carrying out their 
duties. If the signed research consent form is inspected or copied, the hospital will use 
reasonable efforts to protect your privacy. The results obtained from this study will be 
published in the scientific journals, but no information about your identity will be 
disclosed.  
If I have questions or concerns about this research study, whom can I call? 
You can contact the following person for your questions about the study 
       Dr.V.J.Subha 
       PG Registrar 
      Department of Microbiology, Christian Medical College, Vellore - 632004 
      Phone: 0416 2282588, 9486082377 
                                               
 
 
 
 
 
 
 
 
 
  
                                             INFORMED CONSENT FORM 
 Study Title: Virological characterization of BK virus among HIV-1 infected 
individuals and its association with immunosuppression  
 Study Number: ____________ 
 Subject’s Name: _____________________________________  
 Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions.  
 
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected.  
 
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look 
at my health records both in respect of the current study and any further research that may 
be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released 
to third parties or published.  
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
 (v)  I agree to take part in the above study.  
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
Or 
 
 
 
 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name and Address of the Witness: ______________________________ 
 
 
 
PATIENT PROFORMA 
Study Title: Virological characterization of BK virus among HIV-1 infected individuals and its 
association with immunosuppression 
Study number:                                                                                 Date: 
Name:         
Hospital number: 
Date of birth / Age:                                                                         Sex: 
Address: 
State: 
Mother tongue: 
Marital Status: 
Clinical diagnosis: WHO I/II/III/IV - will be done by the physician (Co- investigator) 
Date of HIV diagnosis: 
  
History of renal disease  
Symptoms: Decreased urine output  
                       Macroscopic Hematuria  
                                         Pedal oedema  
                                                    Dysuria 
                      Suprapubic / flank pain  
                                                    Myalgia 
 
Already diagnosed renal disease:  
If yes, Cause -  
             Mode of diagnosis -  
History of organ transplantation: 
 
History of chronic diarrhoea  
                        Weight loss >1m  
                                            Fever 
                                           Cough                      
 History/Diagnosed OI/other infections (This information will be obtained 
retrospectively from the clinical workstation/patient work chart/discussion with the 
clinician about the patient for WHO classification): 
a)Tuberculosis, b)Candidiasis, c)Herpes zoster, d)Pneumocystis carinii pneumonia, 
e)Bacterial pneumonia, f)Salmonellosis, h)Toxoplasmosis, i)Cryptosporidiosis, j)CMV, 
k)Cutaneous Fungal infection, l)Pelvic Inflammatory Disease, m)Cryptococcal 
meningitis, n)Histoplasmosis, o)Hepatitis 
 
Follow up   
Date: 
CD4+/CD8+ T cell count: 
History/Diagnosed other infections: 
                                                                                                                                                                                                       
                                                                                                         Sample collected by 
                                                                                                                   Name: 
                                                                                                                   Signature: 

HBK No. Age Sex
Qualitative 
BK result CD4 count
WHO 
stage Geographic region BK VL HIV-1 VL HBK No. Age Sex
Qualitative 
BK result CD4 count
WHO 
stage Geographic region BK VL HIV-1 VL
1 33 F negative 540 1 tamilnadu 0 48 32 F negative 912 1 andhra pradhesh 1616
2 36 M negative 777 1 west bengal 71 49 57 M negative 457 1 tamilnadu 3600
3 36 F negative 465 2 west bengal 2987 50 47 M negative 591 1 andhra pradhesh 5076
4 28 M negative 204 1 andaman & nicobar 4942 51 41 M negative 398 1 andhra pradhesh 37848
5 46 M positive 444 3 tamilnadu 43,240 80574 52 42 M negative 529 1 andhra pradhesh 369
6 29 F negative 1006 1 tamilnadu 649 53 45 M negative 340 4 andhra pradhesh 1450
7 41 F negative 722 1 westbengal 95 54 32 F negative 509 1 tamilnadu 273
8 54 M positive 537 3 andhrapradhesh 8 71 55 44 F negative 874 1 tamilnadu 69
9 35 F negative 442 1 tamilnadu 4986 56 41 F negative 76 4 west bengal 33230
10 39 F negative 711 1 kerala 488 57 42 M negative 354 1 tamilnadu 28800
11 46 M negative 620 1 tamilnadu 1363 58 34 M positive 48 4 jharkhand 1717 16133
12 36 F negative 546 3 tamilnadu 3491 59 41 F negative 582 1 tamilnadu 755
13 32 M negative 694 1 tamilnadu 2209 60 46 F negative 315 1 tamilnadu 73229
14 32 F positive 584 2 tamilnadu 359886 1422 61 22 M positive 31 4 andhrapradhesh 11 358
15 32 M positive 362 1 andhrapradhesh 1 828 62 61 M negative 779 1 andhra pradhesh 43310
16 26 M negative 297 1 tamilnadu 330 63 37 M negative 256 1 tamilnadu 19643
17 35 M negative 93 3 tamilnadu 19598 64 40 M negative 434 1 tamilnadu 26718
18 60 F negative 100 3 tamilnadu 290974 65 36 F negative 675 1 tamilnadu 4021
19 34 F negative 769 3 andhra pradhesh 71 66 50 M negative 331 1 west bengal 448506
20 37 M negative 142 4 andhra pradhesh 5913 67 41 M negative 455 4 tamilnadu 448506
21 34 F positive 459 1 tamilnadu 1421 1596 68 32 F negative 404 1 tamilnadu 3995
22 49 M positive 261 4 tamilnadu 1 12972 69 39 F negative 1300 1 tamilnadu 71
23 37 F negative 677 1 tamilnadu 71 70 37 F negative 480 1 tamilnadu 445
24 30 F negative 630 1 tamilnadu 71 71 29 F negative 790 1 tamilnadu 2107
25 55 M negative 545 1 tamilnadu 53399 72 41 F positive 222 4 andhrapradhesh 88 5115
26 32 M positive 133 1 tamilnadu 9 740312 73 31 M positive 57 3 andhrapradhesh 886 18256
27 58 M negative 281 2 tamilnadu 108 74 68 M positive 527 1 tamilnadu 1 1494
28 23 M negative 755 1 andhra pradhesh 96698 75 31 M negative 459 3 tamilnadu 13488
29 46 M positive 515 2 tamilnadu 3 100816 76 58 M positive 41 4 tamilnadu 6018 460
30 25 M negative 323 1 tamilnadu 2441 77 42 M positive 529 4 andhrapradhesh 27837 0
31 31 F negative 397 1 tamilnadu 3341 78 56 F positive 533 1 andhrapradhesh neg 616
32 38 F positive 1043 1 andhrapradhesh 4 5845 79 29 F negative 140 4 andhra pradhesh
33 37 F negative 351 2 west bengal 6226 80 39 F negative 376 1 tamilnadu
34 38 M negative 116 1 jharkhand 340912 81 38 F negative 329 2 tamilnadu
35 50 M positive 391 3 andhrapradhesh 110 489718 82 58 F negative 392 2 tamilnadu
36 61 M negative 794 1 tamilnadu 1364 83 49 M negative 301 3 andhra pradhesh
37 48 M negative 517 3 tamilnadu 33419 84 47 M negative 152 4 tamilnadu
38 53 M negative 641 1 orissa 0 85 45 M negative 66 4 madhya pradhesh
39 23 M negative 593 1 tamilnadu 6004 86 30 M negative 238 2 tamilnadu
40 26 M positive 24 4 andhrapradhesh 326 385083 87 39 F negative 1176 1 andhra pradhesh
41 51 M negative 457 1 tamilnadu 36727 88 34 F negative 412 1 tamilnadu
42 30 F negative 584 1 tamilnadu 1010 89 46 F negative 375 2 tamilnadu
43 40 M negative 314 1 tamilnadu 376 90 45 M positive 295 1 tamilnadu 1 854028
44 39 F negative 330 4 tamilnadu 862329 91 34 M positive 46 4 assam 582 1051785
45 35 F negative 611 1 tamilnadu 301 92 33 F negative 713 1 tamilnadu
46 40 F negative 142 3 tamilnadu 45393 93 34 F negative 565 1 tamilnadu
47 43 F negative 224 andhra pradhesh 9754 94 32 F negative 756 1 tamilnadu
Details of HIV-1 infected individuals
HBK No. Age Sex
Qualitative 
BK result CD4 count
WHO 
stage Geographic region BK VL HIV-1 VL HBK No. Age Sex
Qualitative 
BK result CD4 count
WHO 
stage Geographic region BK VL HIV-1 VL
95 32 M negative 436 3 tamilnadu 142 46 M positive 75 4 bihar 4 164535
96 35 F negative 117 2 jharkhand 143 41 M negative 734 1 andhra pradhesh
97 44 M positive 18 4 andhrapradhesh 174 1465719 144 50 F negative 740 1 tamilnadu
98 42 M negative 190 3 west bengal 145 63 M negative 221 1 andhra pradhesh
99 40 F negative 486 1 tamilnadu 146 26 M negative 432 1 tamilnadu
100 29 M negative 327 1 tamilnadu 147 33 M positive 310 3 tamilnadu 19 71
101 28 M negative 443 1 west bengal 148 44 M positive 471 1 andhrapradhesh 4474 1709
102 42 F negative 785 1 andhra pradhesh 149 36 F positive 274 1 andhrapradhesh 72 25676
103 37 M positive 343 1 andhrapradhesh 477 43436 150 28 F negative 332 1 jharkhand
104 52 F negative 667 1 andhra pradhesh 151 38 F negative 562 1 kerala
105 40 M negative 176 3 andhra pradhesh 152 38 F positive 665 1 tamilnadu 86 71
106 34 F negative 577 3 andhra pradhesh 153 56 F negative 410 1 tamilnadu
107 59 M negative 359 1 andhra pradhesh 154 40 F negative 294 3 andhra pradhesh
108 36 F negative 377 1 tamilnadu 155 41 F positive 197 1 andhrapradhesh 185 486003
109 30 M negative 167 2 tamilnadu 156 35 F negative 92 1 tamilnadu
110 38 F positive 455 1 tamilnadu 73 21461 157 32 M negative 871 1 tripura
111 35 F positive 31 4 tamilnadu 31 3533 158 42 F negative 414 1 tamilnadu
112 58 M negative 29 3 bihar 159 32 M negative 594 1 andhra pradhesh
113 35 F negative 590 1 tamilnadu 160 42 F negative 515 1 andhra pradhesh
114 45 M negative 479 1 andhra pradhesh 161 27 F negative 445 1 tamilnadu
115 41 M negative 49 4 tamilnadu 162 48 F negative 481 1 andhra pradhesh
116 36 M positive 177 1 tamilnadu 1 532936 163 37 M positive 459 1 tamilnadu 87368 2306
117 42 F negative 610 1 tamilnadu 164 37 M negative 637 1 tamilnadu
118 56 M negative 43 2 west bengal 165 38 M negative 7 4 tamilnadu
119 35 F positive 697 1 tamilnadu 29 87 166 49 M negative tube failure 3 tamilnadu
120 39 M positive 72 3 tamilnadu 26882 267901 167 38 M negative 769 1 andhra pradhesh
121 36 F positive 663 3 andhrapradhesh 95645 11937 168 39 F negative 337 1 tamilnadu
122 35 M negative 271 3 tamilnadu 169 41 M positive 48 4 tamilnadu 1171 5888659
123 34 M negative 437 1 tamilnadu 170 30 M negative 140 3 west bengal
124 37 F negative 483 1 tamilnadu 171 64 M negative 462 1 chattisgarh
125 44 M positive 540 1 tamilnadu 1 1942 172 42 M positive 45 4 tamilnadu 1615 not done
126 59 M negative 636 2 tamilnadu 173 35 F negative 116 1 tamilnadu
127 32 F negative 631 1 tamilnadu 174 25 F positive 613 1 tamilnadu 74 12948
128 37 M positive 312 1 andhrapradhesh 134 117637 175 44 F positive 660 1 tamilnadu 11888 62905
129 30 M positive 455 1 tamilnadu 0 133801 176 38 F negative 47 2 andhra pradhesh
130 52 M negative 31 4 tamilnadu 177 32 M negative 398 1 tamilnadu
131 53 M negative 501 3 andhra pradhesh 178 28 M negative 324 1 west bengal
132 44 M negative 25 4 west bengal 179 28 F positive 719 1 tamilnadu 2 81293
133 55 M negative 521 3 tamilnadu 180 34 F negative 728 1 tamilnadu
134 31 F negative 502 1 tamilnadu 181 61 M positive 451 1 tamilnadu 55 9001
135 46 F negative 441 1 tamilnadu 182 46 F negative 495 1 tamilnadu
136 45 F negative 791 1 tamilnadu 183 46 M negative 64 4 tamilnadu
137 35 M negative 665 3 tamilnadu 184 44 M positive 28 4 tamilnadu 184 39437
138 37 M positive 332 2 andhrapradhesh 268 20833 185 47 F negative 307 1 tamilnadu
139 54 M negative 55 2 tamilnadu 186 49 M negative 701 1 tamilnadu
140 26 M negative 28 3 west bengal 187 40 F positive 206 1 tamilnadu 93 21638
141 30 F negative 28 3 tamilnadu
Details of HIV-1 infected individuals
HBKC No Age Sex BK qualitative BK viral load HBKC No Age Sex BK qualitative BK viral load
1 28 F negative 48 41 F negative
2 27 M negative 49 41 F negative
3 27 M negative 50 39 F positive 2
4 27 M negative 51 42 M positive 34
5 27 F negative 52 40 M negative
6 23 M negative 53 53 F negative
7 36 F negative 54 39 F negative
8 43 F negative 55 49 M negative
9 50 M negative 56 43 M positive 9
10 38 M negative 57 40 M negative
11 26 F negative 58 46 M negative
12 30 F negative 59 49 M negative
13 23 M negative 60 36 F negative
14 28 M negative 61 38 F negative
15 29 M negative 62 37 F negative
16 42 M negative 63 29 M positive 240
17 32 F negative 64 36 M negative
18 32 F negative 65 40 M negative
19 30 F negative 66 35 F negative
20 33 M negative 67 35 F negative
21 31 F negative 68 37 M negative
22 56 F negative 69 37 F negative
23 33 F negative 70 32 M negative
24 33 M negative 71 40 M negative
25 26 F negative 72 31 M negative
26 34 M positive 2 73 37 M negative
27 44 M negative 74 47 M negative
28 41 M negative 75 34 M negative
29 44 M negative 76 41 M negative
30 44 F negative 77 35 F positive 1
31 41 M negative 78 35 M negative
32 39 F negative 79 34 F negative
33 32 M negative 80 37 M negative
34 38 M negative 81 47 M negative
35 42 F negative 82 26 M negative
36 29 F negative 83 38 F negative
37 55 F negative 84 34 M negative
38 53 M negative 85 39 M negative
39 46 F negative 86 47 F negative
40 43 F negative 87 62 M negative
41 42 M negative 88 44 F negative
42 46 F negative 89 49 M negative
43 42 F negative 90 35 F negative
44 45 M negative 91 43 F positive 572
45 45 M negative 92 39 F positive 12
46 47 F positive 7 93 28 F positive 192
47 35 F negative
Details of HIV uninfected healthy controls
